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Time is measured as a moment, hour, day or year as indicated by a clock or
calendar. To someone facing cancer it seems to count backwards from a date determined
by an incurable disease. Even with the advances in research and technology cancer is still a
leading cause of death in the United States as no cure exists. Biomedical research is
constantly struggling with cancer detection, diagnosis, treatment, and prevention.
Currently, cancer detection is expensive, diagnoses are sometimes erroneous, treatment is
invasive, and prevention is a challenge.
The primary goal of the cancer detection is to develop simple non-invasive tests
that indicate cancer risk, allow early cancer detection, classify tumors so that the patient
can receive the most appropriate therapy and monitor disease progression, regression and
recurrence. Currently cancer is often diagnosed though imaging technologies or through
invasive procedures often after the cancer has formed a sizable tumor, or already
metastasized. Methods that rely on measurements of alterations or abnormalities in certain
protein concentrations are promising alternatives for diagnosis and improving patient care.
Since significant interpersonal variation of single protein expression levels are often
observed in patients within a given disease, simultaneous measurement of a collection of
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protein biomarkers may help to lead to more accurate and early diagnosis and offer more
insights to the disease state and characteristics, thereby potentially improving patient care.
The objectives of this thesis are to develop protein sensors that are inexpensive,
sensitive, rapid, use minimal sample volume, have multiplex capabilities, and are
technically simple to use for applications with real cancer patient samples in a point-ofcare setting. Such methods may make cancer diagnoses possible without locating the
tumor, or even before a tumor has formed.
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Chapter One
Introduction

1.1 Goals and Significance
In 1971, US President Nixon declared a war on cancer.1 This was an effort to
raise public awareness of the devastating disease that posed/poses a serious threat on the
human race.2 Since the declaration over 40 years ago we have discovered that cancer can
manifest in hundreds of types and subtypes, affecting almost all organs and tissues.2,3 We
have also learned that cancer cells are extremely complex.2,3 Cancer cells are derived
from instrumental mutations and rearrangements of the human genome.2,3,4,5 These
transformations cause cells to promote the extensive growth of cancer through genetic
and epigenetic reprogramming of regulatory circuits, which corrupt normal cells to
become proliferating cancer cells.

2,3,4,5

However, despite all the progress that has been

made in understanding the nature of cancer the question remains are we winning this
war? According to the World Oncology Forum that met in late 2012 the answer is No.2
Cancer remains a leading cause of death in the United States and through out the
world. It is second only to heart disease.6 More than 1.6 million people are diagnosed
with cancer each year, and this year alone over 585,000 Americans will die because of
cancer, corresponding to 1,600 deaths per day.6 It is evident that as diagnoses are delayed,
the survival rate decreases significantly.

The 5-year relative survival rates among

patients who are diagnosed with either advanced lung, colorectal, or breast cancer are
only 3%, 10%, and 27%.6 However, survival rates among patients diagnosed with
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localized lung, colorectal, or breast cancers are significantly higher at 50%, 90%, and
98%.6 In light of these statistics, diagnosing cancer at an early stage before they
metastasize and become incurable will have a significant impact on cancer survival.
Current methods of cancer detection are often based on imaging technology such
as magnetic resonance imaging (MRI), positron emission tomography (PET), and
computed tomography (CT), which use contrast materials that can distinguish between
different anatomical features.7,8,9,10,11 However, each of these are limited to imaging
giving no quantification of cancer and limited information of the onset of cancer.
Furthermore these imaging techniques may be unavailable in limited resource
settings.7,8,9,10,11 Other techniques are based on cell morphology and microscopy which
involve invasive biopsies to observe cancerous cells in tissue samples.12,13 These tests are
not individually conclusive as tissue removal can often miss cancerous cells especially at
early onset of the disease.12,13 Alternatively, patients may be screened for cancer without
undergoing any invasive procedure by assaying bodily fluids to test for levels of cancer
biomarker proteins.14, 15
In general biomarkers are chemical, physical, or biological parameters that can be
used to indicate a biological or disease state.16 They can be used to develop target
therapies, predict risk, help in early screening, forecast how well a patient will respond to
treatment, and monitor disease progression.16 Specifically, a tumor marker is any
molecule produced by a tumor or by a host in response to a cancer cell that can be
objectively measured as an indicator of a cancerous process.16,17 These biomarkers can be
grouped into a multitude of categories including proteins, glycoproteins, oncofetal
antigens, horomones, receptors, genetic markers and RNA molecules. 16,17
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Overall, most biomarker studies are aimed at understanding the pathobiology of
the disease.18,19 In the case of cancer we know that as normal cells evolve to cancer cells
they acquire a succession of hallmark capabilities that enable them to become
tumorigenic and ultimately malignant.4,5,18 These “Hallmarks of Cancer” as described by
Hanahan and Weinberg include sustaining proliferative signaling, genome instability and
mutation, insensitivity to growth inhibitory (antigrowth) signals, avoiding immune
destruction, limitless replicative potential, tumor promoting inflammation, sustained
angiogenesis, evasion of programmed cell death, deregulating cellular energies, and
tissue invasion and metastasis.4,5 These capabilities are shared in most if not all types of
human tumors and are a result of genetic alterations that include gene rearrangements,
point mutations, and gene amplifications.2,4,5,19 However, it is evident that the functional
endpoint of these genetic alterations lies at the protein level.20,21 Genetic mutations can
modify protein signaling pathways and various protein interactions that make up the
circuitry within the cell (Figure 1.1).20,21 Therefore, it is clear that mining of biological
samples at the protein level will provide useful protein candidates that can serve as
markers for disease states. 20

!

$!

WNT

Anti-growth factors
(e.g. TGF!)

Disheveled

Frizzled

GSK-3!

TCF

!-Catenin

E-Cadherin

Cells

TGF!R

p16

APC

Cycl D:CDK4

ECM

Rb

Integrins

FAK
Cas

p15

Smads

Rac

P13K

CdC42

Crk JNKs

Jun

HPV E7

p27

E2Fs

p21

Cycl E:CDK2

MKKs
Growth Factors
(e.g. TNF-#)

Grb2
SOS

RTK

Hormones
(e.g. Bombesin)

7-TMR

Ras

G-Prot

Raf

MEK

MAPK ELK

CREB

PKA

Ad Cycl

Changes
in Gene
Expression

Cell
Proliferation
(cell cycle)

ARF

DNA
damage
sensor
p53
Bax

MDM2
Mitochondria

(e.g. Estrogen)

NHR (e.g.ER)
NF-"!

PKC

Survival Factors
(e.g. IGF1)

RTK

P13K

Akt

Akka

NF-"!
Stat 3,5

l"!

Bcl 2
Cell Death
(Apoptosis)

Caspase 8

Caspase 9
Stat 3,5

Stat 3,5
Bad
Jaks

Abnormality
Sensor

FADD

Fas

Cytochrome C
Mitochondria
Blm, etc

Bid
Death
Factors
(e.g. FasL)

Cytokine R

Cytokines
(e.g. Il-3/6)

Figure 1.1 Protein Circuit of the Cell. Adapted from reference (4).

Advancements in the field of proteomics have lead to the detection of hundreds to
thousands of protein cancer biomarkers through the use of both 2-D gel electrophoresis
and mass spectrometry.17,20,22 However, despite the tremendous efforts that have been
made there are less than two dozen cancer proteomic biomarkers approved by the FDA in
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the United States for clinical use.17,23 Furthermore, these biomarkers have significant
limitations. Many biomarkers can be indicative of more than one disease such as serum
PSA which is elevated in conditions such as benign prostatic hypertrophy, prostatitis, or
even with excess levels of testosterone.19,24 Therefore, efforts have been focused on
development of panels of biomarker proteins that are specific to the disease.14,19,22,24,25,26
Assaying panels of these specific protein biomarkers would further minimize false
positives and negatives predicted values. In addition, measurement of multiple protein
biomarkers holds enormous potential in simplifying disease diagnosis and guiding
personalized patient care strategies.19,26
Once protein biomarkers are identified, the next step is to develop an assay with
suitable for point-of-care diagnosis.17,19 In order for these assays to be effectively used in
a clinical setting they must be inexpensive, multiplexed, require minimal sample volume,
reduced turnaround times (shorter assay times), require little to no expertise to operate,
and exhibit a wide dynamic range in complex media, such as serum.17,19,27 Therefore, the
goal of this dissertation is to address the aforementioned difficulties in production of a
POC sensor. In order to achieve these objectives efforts will be focused on development
of ultrasensitive multiplexed electrochemical immunoassay systems that combine
nanostructured sensor electrodes and massively multi-labeled detection microparticles
into simple modular microfluidic devices.

1.2 Point of Care Protein Detection Systems
The capability to measure the levels of individual proteins in cells tissues, extracts
and biological fluids has been a long-standing and critical component in the progress of
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both life science research and clinical practice.28 Currently, most cancer biomarker
protein testing for clinical diagnoistics takes place in dedicated centralized laboratories
using large, automated analyzers.27,29 This requires samples to be transported to a testing
site, thereby increasing on wait times, increased administration as well as medical
cost.27,29 Development of point of care devices are hoping to change these facts by
providing rapid and reliable quantitative results anytime and anywhere, for example in
clinics and hospital emergency departments.27,29 However, in order for a device to be
used in the clinical setting current biological testing systems must be reduced to the size
of a handheld devices that require only minimal amounts of sample and reagents, while
maintaining a multi-analyte, high-throughput, specific and sensitive assay.27,29
There are numerous assay formats that exist to measure proteins in solutions
(enzyme-linked immunosorbent assays, ELISAs, on cell surfaces (flow cytometry),
within cells (immunohistochemical and immunoflorescent microscopy), and within
organs (invivo imaging with labeled antibodies).28 However, for nearly forty years
ELISAs, have served as the workhorse for protein detection.30 Today they are still the
most widely used clinical protein detection systems, and have been labeled as the gold
standard for single-protein measurement. ELISAs employ the use of a sandwich
immunoassay.19,31,28 In this format, a primary antibody (Ab1), which is specific to its
antigen (target protein), is attached to the bottom of a well plate. After antigen is bound to
these antibodies, a second enzyme labeled detection antibody (Ab2) attaches which
provides both a detection and amplification. Once detection antibodies are in place a
substrate chemical is applied which is converted by the enzyme label, causing a change in
color of solution, which produces a visible signal that are typically read by a
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chromogenic reporter (Scheme 1.1).30 ELISA’s are commercially available, have low
detection limits in pgmL-1 range, and are highly specific for their targeted protein.19,31,28
However, ELISAs are timely, labor intensive, and require large sample volumes.
Additionally, ELISA lack high sensitivity needed to detect multiple biomarkers.

Sandwich Immunoassay
Enzyme Labeled
Antibody
Target Protein

Antibody

Chromogenic reporter
(ELISA plate reader)

Well Plate

Scheme 1.1 Full sandwich immunoassay protocol for ELISA based assays.

Advancements in the field of mass spectrometry based proteomics have enabled
multiple biomarker mesurements to be achieved with good sensitivity.14,22 Nevertheless,
they are currently too expensive and technically complex for routine clinical diagnosis.
Alternatively, there are several commercially available analyzers for multiplex
!
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determination of up to 10 selected target proteins, that can reach low detection limits for
1-100 pg mL-1 in serum.19,32 These systems are based on fluorescence (Luminex, Myriad
RBM), electrochemiluminescence (Roche Diagnostics, Mesoscale Discovery), or surface
plasmon resonance (Horiba Inc, BIO-RAD).32,29,33 However, each of these commercial
instruments require specialized consumables and sometimes equipment, such as sample
well plates, chips, laser sources and reagent kits which are expensive and therefore limit
their usefulness for point of care applications where resources are limited.32,29,33
Electrochemical detection strategies on the other hand offer robust and quantitative
measurements using low-cost and simple instrumentation with the ability to be
incorporated into a portable device.32,34 The glucose meter, which currently has control
over 85% of the entire POC biosensor market is based on electrochemical detection.27 In
addition the coupling of electrochemical devices with nanomaterial’s offers unique
multiplexing capability for multiplex detection of multiple analytes.19,35,36

1.3 Electrochemical based Protein Detection
Electrochemical based biosensors determine the level of protein analyte of interest
by detecting changes in either potential, current, capacitance, conductance or impedance
caused by a specific biorecognition reaction.29,34,37 The biosensor intimately couples a
biological recognition element to an electrode transducer, which converts the biological
recognition event into a useful electrical signal.29,34 There are several common electrode
transducers such as impedance, conductometric, protentiometric, and amperometric that
are used in biological electrochemical sensing.29,34,37 Impedance transducers rely on
measuring resistive and capacitive changes that are in response to a biorecognition
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event.38 Typically, a biorecognition element is bound to the surface of an electrode and
the frequency is varied to obtain an impedance spectrum.38 The resistive and capacitive
components of impedance are determined from an in phase and out of phase current
responses.38 The interfacial impedance is a result of analyte binding to the biorecognition
element.38 Conductometric transduction involves measuring the change of conductive
properties of a sample solution.37 This usually involves AC potential to be applied across
two metal electrodes causing a current flow.37 In the event of biorecognition of an analyte
the ionic composition changes, using a resistance meter the change in conductance can be
observed.37 Potentiometric sensors on the other hand generate their signals by concerting
the biorecognition reaction into a potential signal through the use of ion selective
electrodes.34,37 These ion selective electrodes feature a membrane that exclusively binds
with the charged ion of interest, this then causes an accumulation of a charge potential
that can be read by a impedance voltmeter.34,37 However, despite the obvious advantages
of using these unlabeled electrochemical biosensors they still require significant future
development in terms of both cost and in sensitivity to test clinical samples.19
Alternatively, amperometric biosensors function by applying a constant potential and
monitoring the current associated with the redox (reduction or oxidation) of an
electroactive species that is involved in the recognition process. Amperometric sensors
offer high sensitivity and wide linear dynamic ranges making them highly attractive
candidates for clinical protein detection.29,34,37
Nearly thirty years ago Heineman and Halsall pioneered the electrochemical
detection of proteins based on applying enzyme-linked immunosorbent assays to an
electrode surface.39 Such protocols rely on labeling the antibody or antigen with an
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enzyme that instead of causing a change of color as in ELISA based methods generates
an electroactive product that can be detected amperometrically.39,40,41 The enzyme label
applied by the Heineman group was alkaline phosphatase, which produces electroactive
products.39,40,41 Using this approach, the capture antibodies dwell in a flow system
upstream of the detector.

39,40,41

Products from the enzyme label are then transported to

the electrode by fluidics.

39,40,41

They are able to obtain excellent detection limits in the

pg/mL to ng/mL range for small molecules and proteins. 39,40,41
As time progressed significant efforts were made to develop self-contained single
analyte

enzyme-linked

electrochemical

immunosensors.42,43,44

These

sensors

predominately feature antibodies being attached directly to the electrode surface, these
antibodies are able to capture their target protein of interest (Scheme 1.2). 42,43,44 Once the
protein target is captured, an enzyme labeled secondary antibody binds and detection is
carried out all on the same surface. This sandwich immunoassay format is the most
selective and sensitive for protein detection. 42,43,44
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H2O2

HRP (Fe III)

Capture Antibody
HRP-Detection Antibody

H2O

HRP (Fe IV= O)

O

OH

O

OH

2 e- 2 H+

PG Electrode

Protein

Scheme 1.2 Full sandwich immunoassay built upon the surface of a single electrode.
Amperometric signal generation carried out by Horserasish peroxidase.

Alternative enzymes labels such as horseradish peroxidase (HRP) are widely used
for ELISAs and for electrochemical based immunosensors.19,45 Horseradish peroxidase
(HRP) is a member of the ferroprotoporphyrin group of peroxidase.46,47 It is a single
chain polypeptide containing a central iron heme group. The heme group is capable of
catalytic oxidation/reduction by hydrogen peroxide (Scheme 1.2).46,47 Once activated by
hydrogen peroxide the iron heme is converted to its oxidized form (FeIV= O) that can be
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reduced on electrodes at low potentials.47 Almost all electrochemical based protein
detection within this dissertation will be carried out using this paramount enzyme label.
In addition to both horseradish peroxidase and alkaline phosphatase many other
labels for electrochemical detection of proteins have been used such as glucose oxidase,
conductive polymers, electroactive metal ions and complexes, and liposomes that are
loaded with electroactive compounds.48,49,50,51 However, the most sensitive of detection
schemes have employed strategies including dissolvable nanoparticles, and nanoparticles
with multiple enzyme labels or multiple redox probes.36,49,50,52,53,54,55,56 Employing these
approaches investigators are able to achieve high signal amplification by providing many
signal generating species for each analyte that is captured on to the sensor surface.

1.4 Nanoparticle labeled Immunoassays
The ability to amplify your detection single is critical to the sensitive detection of
proteins. The first reports of dissolvable nanoparticle labels employed in electrochemical
based immunoassays were by Dequaire et al.57 Here, gold nanoparticles were bound to
detection antibodies to amplify the electrochemical signals using a sandwich
immunoassay approach within microwells.57 Once particle were bound to their target
analytes, an acid solution is applied to the microwells and the metal ions are released and
detected by anodic stripping voltammetry.57 Similar strategies were further developed by
Wang et al to achieve even greater sensitivity using gold nanoparticles to catalyzed silver
precipitation enhancing the release of ions.49 In addition to gold and silver, CdS quantum
dots decorated on magnetic beads were also used as labels in electrochemical stripping
analysis.49 Alternatively, detection antibodies labeled with either nanoparticles or
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polymer beads loaded with electroactive labels such as ferrocene derivatives can be used
as labels (Figure 1.2).49,54,56
As previously discussed both horseradish peroxidase and alkaline phosphatase
can serve as excellent enzyme electrochemical labels.19,39,45 Attaching multiple copies of
these enzyme labels to nanoparticles can greatly enhance the sensitivity of the
electrochemical detection (Figure 1.2).58,59 Wang et al was the first to report the use of
nanoparticle labeled with multiple enzyme labels for the ultrasensitive detection of DNA
(Figure 1.2) .60 Multiwall carbon nanotubes were decorated with thousands of copies of
alkaline phosphatase and detection antibodies (or probe DNA) to achieve fM detection of
IgG in buffer (Figure 1.2).60 Further enhancements to sensitivity of these protocol were
achieve by using layer-by-layer film deposition of alkaline phosphatase with oppositely
charged polyions to the surface of carbon nanotubes resulting in extremely low detection
limits of 70 aM for IgG in butter.61
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Ab2-DNA
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Figure 1.2 Amplification approaches for electrochemical immunosensor using
nanoparticles or other moieties attached to a secondary antibody (Ab2). Adapted from
references (19,35).

Our own research team has employed the use of multiple enzyme labels in
designing immunosensor protocols for a library of known cancer biomarker
proteins.19,51,52,62,63,64,65

Initially

conventional

detection

antibodies

labeled

with

horseradish peroxidase were employed, this was quickly replaced by more sensitive
detection schemes using streptavidin-biotin complexes.64 Here, biotinlyated detection
antibodies are conjugated to streptavidin labeled HRP which can provide 14-16
horseradish peroxidase labels to each detection antibody increasing the sensitivity of the
electrochemical detection.64 Further enhancements to signal amplification were achieved
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by conjugating horseradish peroxidase to carbon nanotubes and eventually to magnetic
beads, which enable up to half a million HRPs to be bound.19,51,52,62,63,65
Magnetic bead based amplification strategies offer many advantages over nonmagnetic nanoparticle in terms of the ease of manipulation for labeling, antibody
attachment, and purification of bead bioconjugates with simple and inexpensive
magnets.35,66,67 Typically, paramagnetic beads are employed for magnetic separation and
transport as they become magnetized in an applied magnetic field, yet have zero
magnetization in the absence of a magnetic field.68 These beads have high surface areas
per unit volume, good stability which enable effective antibody attachment.66,67,68 In
addition these beads are commercially available with sizes ranging from 100 nm to 50
µm, and with coatings of either organic functional groups or precoated biomolecules that
can bind to specific partners.59 Using these commercially available magnetic particles we
have been able to achieve ultra low detection limits down to the aM range in sensitivity
for the electrochemical detection of clinically relevant proteins.69 Further enhancements
to sensitive electrochemical detection of proteins can be achieved by employing
nanoparticles at the sensor surface.

1.5 Nanoparticle Platforms for Electrochemical Detection
Due to the fact that reactions are generally carried out in close proximity to the
electrode surface, the electrodes themselves play critical roles in performance of an
electrochemical biosensor.37 Therefore, the detection ability of each sensor is based on
selected function of a specific electrode, electrode material, its surface modification
and/or its dimensions.37 Tailoring electrode surfaces to achieve unique properties has
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expanded tremendously with advent in nanofabrication.70 Here scientist are controlling
the electrode surface architecture on the nanoscale whether it be through nanomaterials,
organic monolayer modification, or using combination of both modification of layers
involving organic monolayers and nanomaterials.70 These nanoparticle based surfaces
offer large surface areas that enable attachment of multitudes of capture antibodies and
offer intricate surface structures that provide better access of proteins analytes to the
capture antibodies.71 Methodologies for production of nanostructured immunosensors
include attaching films of carbon nanotubes, gold nanoparticles, or even controlled
electrodeposition of noble metals to obtain porous nanostructured surfaces.19,52,62,72,73,74
Development of nanoparticle platforms on electrode surfaces began in the early
1990s.75,76,77 These platforms were initially used to increase their electrochemical signals
via their high surface-to-volume ratios. By increasing the electroactive surface area
investigators are able to reach lower detection limits and higher sensitivity to analytes.75
Gradually, efforts were focused on their application to bioconjugated systems.70 However,
in order to bioconjugate a nanoparticle to say an antibody the particles themselves need to
possess a means of attachment such as coatings of either organic functional groups or
precoated biomolecules that can bind to specific partners.
Carbon nanotubes are commonly functionalized by treatments with strong acids
such as HNO3 and H2SO4.78,79,80 These treatments shorten the length of the carbon
nanotubes and add terminal carboxylate groups, which can then be used for conjugation
with biomolecules (Figure 1.3).78,79,80 Our own research team has employed shortened
single wall carbon nanotubes, in an upright format, called SWCT forests for sensitive
detection of PSA.52,53,63 To develop these films, end-carboxylated SWNTs are self-
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assembled from DMF solutions onto thin iron oxide-Nafion underlayers to an electrode
surface.52,53,63 Antibody attachment is accomplished through standard amide coupling
using 1-(3-(dimethylamino)propyl)-3ethylcarbodiimide hydrochloride (EDC) and Nhydrosulfosuccinimide (NHSS).52,53 Using the aforementioned protocols and combining
SWCT forest sensors with multilabeled CNT-HRP-Ab2 particles were able to accomplish
up to a 10-15 fold increase in surface concentrations of attached antibodies compared to
flat carbon surfaces, which lead to a 10-fold signal enhancement in electrochemical based
immunoassays.63,65
Alternative strategies for achieving nanoparticle-based platforms for ultrasensitive
detection of proteins employed by our research group were to use densely packed films of
5nm gold nanoparticles (AuNP).62 The AuNPs used here are protected by a monolayer of
glutathione molecules that analogous to the SWNT provide carboxylate groups to the
sensor surface allowing for antibody attachment.62 Films were fabricated on electrode
surfaces

by

depositing

a

0.3-0.5

nm

under-layer

of

cationic

poly(diallydimethylammonium) PDDA, washing, and then depositing 5 nm glutathionedecorated gold nanoparticles (GSH-AuNPs) (Figure 1.3).62 Similarly, antibodies were
attached to glutathione-protected AuNPs using EDC/NHSS amidization.62 High
sensitivity of these sensor electrodes was further obtained by using 1µm magnetic beadAb2-HRP bioconjugates with 7500 HRP labels.62 These sensors delivered both high
sensitivity and low detection limits for PSA in serum, which was eight fold lower than
that obtained by our previously mentioned SWCNT forest sensor.62 Further comparison
between both the SWCNT and AuNP platforms were accomplished for the determination
of IL-6, a clinically relevant biomarker protein in serum (Figure 1.3).64 Here,
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immunoassays featured biotinlyated detection antibodies conjugated to streptavidin
labeled HRP.64 Again, the AuNP platform was able to achieve lower detection limit of 10
pg mL-1, a 3-fold better than achieved by the SWCNT sensor.64 Furthermore, the AuNP
sensors delivered a large linear dynamic range of 20-4000 pg mL-1, covering almost of
the clinically relevant range for this cancer biomarker.64 These current strategies of
combing nanostructured electrodes with massively labeled detection particles were
expanded further for multiplex determination of proteins on sensor arrays.
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Figure 1.3 The development of the immunosensor for IL-6 on both A) the surface of
SWNTs and B) GSH-AuNPs. C) The catalytic mechanism for HRP’s electrochemical
detection. (The image of IL-6 was created with Protein Workshop from Xu, G. Y.; Yu, H.
A.; Hong, J.; Stahl, M.; McDonagh, T.; Kay, L. E.; Cumming, D. A. J. Mol. Biol. 1997,
268, 468–481).
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1.6 Electrochemical Multiplex Protein Arrays
Multiplex protein measurement is vital to understanding the pathobiology of
disease states. Proteins constantly function with networks pathways, complexes and
families (Figure 1.1).28 Consequently, actions of individual proteins are not only reliant
on their abundance, but also on the results of interacting, antagonistic and synergistic
proteins.28 The pathobiology of oral mucositis is an excellent example of the complex
behavior of proteins that will be discussed in later chapters of this thesis. Measurements
of single biomarkers are thus not very advantageous to understanding the pathobiological
state. Therefore, research efforts in the field of electrochemical protein measurement are
focused on multiplexing.
Two of the most common approaches used for multiplex electrochemical protein
detection are the bar code labeling and secondly multi-electrode arrays.19,81,82 The bar
code approach employs a series of nanoparticles or quantum dots generating dissolvable
metals that posses’ different reduction potentials using similar approaches to Dequaire et
al.57,83 Liu et al employed an example of this multiplexing approach for the simultaneous
electrochemical detection of !2-microglobulin, IgG, bovine serum albumin, and Creactive protein.83 Here, lead sulfide, cadmium sulfide, zinc sulfide and copper sulfide
colloidal crystals were conjugated to antigen specific antibodies, which when dissolved
yielded Pb2+, Cd2+, Zn2+, and Cu2+ ions.83 High sensitivity detection of each of these
proteins was achieved using stripping voltammetry.83 Extensions of these bar code labels
were further developed by the use of striped microrods, alloy nanowires and multiple
metal spheres.49 However, these multiplex strategies are restricted by the number of
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different metals available and by resolution of each of the metal oxidations within the
electrochemical potential scale.81
The second approach to multiplex electrochemical detection involves using multielectrode arrays where each electrode has a different antibody attached (Figure 1.4).19,81,82
Wilson et al using arrays of iridium oxide electrodes applied an early example of this
array format. The pair of iridium oxide electrodes using alkaline phosphatase as the
enzyme label achieved simultaneous detection of two-cancer biomarkers "-fetoprotein
and carcinoembryonic antigen with a detection limit of 1 ng mL-1.84 This approach was
further extended to an 8-electrode array for the simultaneous detection of seven cancer
biomarkers with detection limits down to 2 ng mL-1.85 While this method showed good
correlations with standard ELISAs for proteins in serum they stilled lacked the sensitivity
to reach clinically relevant ranges for many biomarker proteins.81 Alternatively, Wei et al
was able to achieve detections limits down to the fg mL-1 for detection of oral cancer
protein biomarkers using a 16-sensor electrochemical chip coated with a DNA
dendrimer/ conducting polymer film.86
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Figure 1.4 The multiplexed 8-electrode array with attachment of multiple proteins (in
this case 4, shown in different colors) with duplication, each electrode being measured
simultaneously.

In order to demonstrate these ultralow detection limits for multiplex detection of a
collection of proteins our own reach team as previously described combines the use of
nanostructured electrodes with massively labeled detection particles. Chikkaveeriah et al
demonstrated an early example of our own array format consisting of 4 bundled
electrodes for the simultaneous detection of four prostate biomarkers.87 Clinically
relevant ranges for each biomarker were achieved using these electrode arrays coated
with SWCT forest and multiply labeled with streptavidin-HRP conjugates.87 Further
extensions of these protocols were carried out using AuNP films on commercially
available carbon screen printed arrays as well as low cost in house fabricated inkjet
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printed 8-electrode microfluidic arrays that will be discussed in later chapters of this
thesis.

1.7 Microfluidic Electrochemical Detection
Microfluidic immunosensors offer many remarkable features for point of care
detection such as requiring minimal sample volumes (often only in nanoliters), high
surface to volume ratios which enables for shorter assay times, and degrees of
automation.88,89 Moreover, these microfluidic immunosensors have the ability to be
integrated with other microanalytical functions such as mixers, valves, as well as
detections that greatly enhance its analytical performance to development of a total
micro-analysis system.88,89 In addition to pioneering electrochemical immunosensing the
Heinemann group was among the first to integrate microfluidics with electrochemical
protein detection.90 Using their alkaline phosphatase enzyme label, Heinemann and coworkers developed a magnetic bead based immunoassay system within a glass
microfluidic device to achieve detection limits of 50 ng mL-1 within 20 min assays.90
Microfluidic devices in addition to being fabricated by glass may also be
fabricated using polymers such as poly(dimethylsiloxane), or PDMS.91,92 PDMS is a soft
elastomer that is optically transparent.91,92 The soft elastomer is the most widely used
material in academic microfluidics as it easy to fabricate by replication of molds, highly
flexible, and biocompatible.91,92 In addition to its easy fabrication it has the ability to be
sealed to itself or other substrates both reversible or irreversibly without an adhesive.91,92
Substrates such as silicon, glass, or plastics for PDMS have been widely used for easy
fabrication of lap on chip devices.91,92 Ko and co-workers demonstrated an early example
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of lab on chip featuring PDMS devices with integrated electrodes.93 Here, Ko and coworkers develop their electrochemical microfluidic device by placing their patterned
PDMS ontop a poly(dimethyl methacrylate) PMMA substrate containing gold
electrodes.93 In a similar format our research team produces our microfluidic
electrochemical devices.
Our first microfluidic electrochemical detection system was fabricated using a
machine molded 63 µL PDMS channel that was sandwiched between 2 hard PMMA
plates, connected by PEEK tubing to a pump and sample injector (Figure 1.5A).94 This
detection chamber easily houses our 8-electrode sensor immuno-arrays as well as both a
platinum (Pt) wire counter, and silver/silver chloride (Ag/AgCl) reference, electrodes
(Figure 1.5A).94 Prior to being incorporated in the microfluidic device these arrays were
coated with sequential layers of the polycation PDDA and GSH-AuNPs as previously
described to attach antibodies through primary amine groups to each electrode surface.94
Protein analytes were captured offline in microcentrifuge tubes using antibody conjugate
magnetic beads coated with tosyl groups that allowed for the attachment an estimated
200,000 HRP labels per bead.94 Once protein analytes were captured the beads were
washed, magnetically separated, and injected into the microfluidic detection system
(Figure 1.5B). 4 Employing this microfluidic device along with offline capture of protein
analytes interleukin-6 and prostate specific antigen Chikkaveeraiah et al was able to
achieve detection limits in the sub pgmL-1 range in 1-hour assays.94 This system was
further extended to the multiplex detection of four protein biomarkers, including
interleukin-6, interleukin-8, VEGF, and VEGF-C for clinical diagnostics of oral cancer.95
Using streptavidin-derivatized beads and biotin-labeled HRP and Ab2 lead to increase in
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enzyme labels (400,000 HRP) enabling for ultra low detection limits to be achieved (550 fg mL-1) in 50 min assays.95
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Figure 1.5 (A) The disposable 8-electrode array incorporated into the microfluidic device
consisting of soft PDMS channel and to PMMA plates, the top containing ports for both
inlet and outlet for fluid to flow threw. The top PMMA also contains both the Pt counter
and Ag/AgCl reference electrodes. (B) The experimental set up for the microfluidic
device containing the 8-electrode potentiostat and computer readout.

In order to achieve further degrees of automization within our microfluidic
electrochemical detection we expanded our microfluidic design to include a capture
chamber upstream of the detection chamber to replace the off-line capture step.96 This
new design enables most of the immunoassay steps to be incorporated into the
microfluidic device, requiring only loading of reagents, samples and wash solutions by
the operator.96 Further application of this modular microfluidic device will be discussed
in later chapters of this dissertation.
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1.8 Summary/ Overview of Dissertation
Cancer is a very complex disease with many signal transduction pathways, and
genomic alterations, not to mention the many types and sub-types there are in existence.3
Therefore, measurement of levels of specific biomolecules, such as certain proteins, may
give further insight to the origin as well as the severity of the disease state.26,19 However,
for accurate diagnosis it is essential to measure panels of these protein biomarkers.19,36,97
Thus, there is a great need for simple high throughput sensors that address all the needs
of a point-of-care setting (i.e. low-cost, multiplex, high sensitivity, minimal sample
consumption, technical simplicity).19 This dissertation aims to address these
aforementioned requirements through the development ultrasensitive microfluidic
electrochemical

immunoassay

systems

that

are

based

on

simple

analytical

instrumentation in order to achieve high sensitivity and low detection limits for protein
detection.
Chapter 1 provides an introduction to point of care sensor designs,
electrochemical based protein detection strategies, and the important links between
advancements in the field of nanomaterial science and electrochemistry. Furthermore,
this chapter highlights the importance of microfluidics in the translation of these sensor
designs to portable point of care detection systems. Discussions of the pioneering
research on these various topics described in this chapter provide a concrete foundation to
the further work that will be presented in this dissertation.
Chapter 2 describes the fabrication of a low cost sensor array. Thin film electronic
devices hold enormous potential for the fabrication of low cost sensors that may be
incorporated into next generation microfluidic devices. We employed a non-contact
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fabrication method of inkjet printing to produce gold nanoparticle (AuNP)
electrochemical arrays on plastic, with a unit cost of only 20 cents per array. These arrays
were fabricated from ink made of dodecane thiol-protected gold nanoparticles
synthesized in-house and were soluble in toluene. This AuNP ink was then printed on to a
flexible, heat resistant polyimide Kapton substrate. Once printed the arrays were then
annealed and insulated with a Kapton precursor layer, poly(amic acid) (PAA). These
results demonstrated that an elegant, cheap, and simple technique for fabricating AuNP
arrays by direct inkjet printing is capable of being incorporated into a next generation
microfluidic device for the electrochemical detection of proteins.
Chapter 3 explains the integration of these low cost inkjet printed sensor arrays
into a simple microfluidic device for low sample volume detection of two cancer
biomarker proteins, interleukin-6 (IL-6) and interleukin-8 (IL-8) within 8 min (Figure 2).
Conventional immunoassays often take hours to complete; however, more rapid assays
are needed for point-of-care sensing and surgical applications in cancer diagnostics.
Sensor arrays are fabricated as described in Chapter 2. The resulting gold sensor elements
are then coated with a self-assembled monolayers providing functionality to attach
capture antibodies to their surfaces. Magnetic beads of 1 µm diameter derivatized with
~300,000 horseradish peroxidase labels (HRP) and thousands of antibodies are developed
to capture the biomarker proteins from serum samples off-line (outside the microfluidic
device setup) to provide high sensitivity and ultralow detection limits (DLs). The results
obtained in Chapter 3 indicate that this fast immunoarray protocol could be employed for
rapid detection of biomarker proteins in surgical samples or to detect inflammation
during cancer therapy.
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Finally, Chapter 4 describes a more user-friendly microfluidic system by adding a
reaction chamber for automated on-line capture and detection of three pro-inflammatory
cytokines and C-reactive protein. This protein biomarker panel was designed to assess
risk for oral mucositis, a painfully debilitating disease that results from high dose
radiation therapy in oncology patients. These protein analytes are captured from
biomedical samples in an on-line microfluidic chamber by thoroughly labeled magnetic
beads, then magnetically separated, washed, and introduced into the detection chamber
housing an 8-electrode screen printed carbon immunosensor coated with glutathione-gold
nanoparticles (GSH-AuNP). Ultralow detection limits of 10 fg/mL were achieved for
simultaneous detection of the four protein biomarkers. Accuracy and diagnostic utility of
these microfluidic arrays were demonstrated by measuring the levels of the four
biomarker proteins in oral mucositis patient serum samples and comparing with standard
ELISA. The use of microfluidic immunosensors to measure concentrations of elevated
biomarkers holds promise for accurate, low cost, and rapid determination of projected
risk of OM that can be used by dentists and oncologists for patient management.
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Chapter Two
Inkjet-Printed Gold Nanoparticle Electrochemical Arrays on
Plastic

2.1 Abstract
Thin film electronic devices hold enormous potential for the fabrication of low
cost sensors that may be incorporated into next generation microfluidic devices. We
employed a non-contact fabrication method of inkjet printing to produce gold
nanoparticle (AuNP) electrochemical arrays on plastic, with a unit cost of only 20 cents
per array. These arrays were fabricated from ink made of dodecane thiol-protected gold
nanoparticles synthesized in-house and were soluble in toluene. This AuNP ink was then
printed on to a flexible, heat resistant polyimide Kapton substrate.The inkjet-printed
working electrodes had reproducible surface areas with RSD < 3%. These results
demonstrated that an elegant, cheap, and simple technique for fabricating AuNP arrays by
direct inkjet printing is capable of being incorporated into a next generation microfluidic
device for the electrochemical detection of proteins.

2.2 Introduction
Thin film electronic devices hold enormous potential for the fabrication of low
cost electrochemical sensors. These electronic devices are typically composed of a
conductor, a dielectric, and a semiconductor in a multilayered structure.1 Common
methods in developing these thin-film electronic devices include chemical vapor
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deposition (CVD),2 photolithography,3 screen-printing,4 and stencil printing.5 While each
of these methods allows for well-defined electrode fabrication and insulation, they each
require the creation of a master such as a custom-patterned screen, stencil, or mask for
printing each new pattern.6 Manufacturing these masters is time consuming and
expensive which limits rapid prototyping and mass customization. Inkjet printing has the
capability to circumvent these current limitations by offering the ability to rapidly
produce patterns based on easily modifiable digital files.6
Herein, we describe a digital fabrication method for creating high-resolution
conductive patterns on heat resistant polyimide dielectric sheets. To make printing the
principal platform for patterning flexible conductors, inexpensive functional inks and
substrates must be employed.6 Nanoparticle inks have been used to print highly
conductive tracks.7,8 For these inks, electrical conductivity of the printed features is
achieved by sintering nanoparticles such as silver, gold, and copper through either high
temperature, laser pulsing, or microwave irradiation.7,8 The substrates for these inks
consequently must be highly durable and resistant to high temperature annealing.7,8
Therefore, the heat resistant Kapton polyimide film was selected for the substrates of
these high-resolution electrochemical sensors. For production of our ink gold
nanoparticles were selected. These gold nanoparticles offer many promising features in
producing highly conductive inks as they may be synthesized through a simple liquidphase synthesis yielding nanoparticles that are easily dispersible in organic media.
The synthesis of our AuNPs followed most standard procedures today employing
a reducing agent to solutions containing a metal salt, the metal ions are reduced and
metallic solid particles are nucleated.9,10,11 In our present study AuCl4- was transferred
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from an aqueous solution to toluene (C6H5CH3) using tetraoctylammonium bromide
(N(C8H17)4 )as the phase transfer catalyst.9,10,11 The organic phase was then separated and
reduced with sodium borohydride in the presence of dodecanethiol (C12H25SH), the
overall reaction is summarized below in two steps where the source of the electrons in
BH4-.9,10,11

AuCl4– (aq) + N(C8H17)4 + (C6H5CH3) -> N(C8H17)4 + AuCl4- (C6H5CH3)

(1)

AuCl4- (C6H5CH3) + C12H25SH (C6H5CH3) + 3e- ->
4Cl-(aq)+(Au)(C12H25SH) (C6H5CH3)

(2)

Following the synthesis of the AuNPs they were dispersed in organic media and printed
using a piezoelectric inkjet printer.
Piezoelectic inkjet printing is a non-contact, high precision printing method with
resolution of ! 20µm.12,13,14 The resolutions of ink-jet printed patterns are controlled by
several factors including the hydrodynamics of the jetted micro-droplets, and the
volatility and viscosity of the constituents of the ink.15 Therefore, careful attention was
applied in production of these material inks. In this paper, we report the first direct inkjet
fabrication and characterization of electrochemical arrays using 4nm nanoparticles and
poly(amic acid) inks on heat resistant Kapton plastic.
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2.3 Experimental
2.3.1 Chemicals and Materials
A Kapton FPPC film 127nm thick was purchased from American Durafilm. These
large polymer sheets were washed with water and ethanol prior to use. Gold (III) chloride
trihydrate,

1-dodecanethiol,

tetraoctylammonium

bromide,

sodium

borohydride,

poly(amic acid) were purchased from Sigma-Aldrich.

2.3.2 Instrumentation
All electrochemical measurements were made using a CHI 1040A eight-channel
potentiostat simultaneously for all eight electrodes at room temperature. All potentials are
reported vs. a common saturated calomel reference (SCE) electrode, and cells employed a
common platinum auxiliary electrode.
A Dimatix Materials Printer (ModelDMP-2800, FUJIFILM Dimatix, Inc. Santa
Clara, CA) was used for inkjet printing. Dimatix 10pL, liquid crystal polymer printer
cartridge were used for all printed inks (Model DMCLCP-11610). Printing patterns were
made utilizing the Dimatix materials printer software. All printing patterns were
developed using Microsoft Paint (Microsoft Inc. Redmond, WA) and imported using the
Dimatix Materials printer with Dimatix Printer Controller software. Each pattern was
printed with 15µm spacing between drops and using a custom printing waveform and
each pattern was printed using a single jet for easy detection of clogs.
Atomic force microscopy (AFM) of gold nanoparticle arrays was done using a
Digital Instruments Nanoscope IV scanning probe microscope, in tapping mode with
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symmetric tip high-resolution TappingMode AFM probes (Veeco Metrology Inc., Model
MPP-11100)
Scanning Electron Micrographs were taken on a Zeiss DSM 982 Gemini FE-SEM
with a Schottky Emitter at an accelerating voltage range from 2 to 4 kV and a beam
current of about 1 mA.

2.3.3 Gold Nanoparticle Synthesis and Ink formulation
Dodecane thiol-protected gold nanoparticles were synthesized as previously
reported by Hostetler et al.10 Briefly, 1.5g of tetraoctylammonium bromide was placed in
a round-bottom flask containing 80mL toluene and 20mL water and stirred vigorously.
432mg of gold (III) chloride trihydrate was added to the solution and mixed for 5mins.
The organic phase was separated and 43.8mL of 1-dodecane thiol was added and stirred
for 10 min. 380mg sodium borohydride was dissolved in 25mL of water and quickly
added to the vigorously stirring gold (III) chloride solution. The solution immediately
turned dark in color and was then stirred for 3hours. Next, the organic phase was washed
with several aliquots of water and toluene was removed by rotary evaporation under
reduced pressure at 50oC. The gold nanoparticles were dispersed in ethanol and filtered,
after which they were washed with several aliquots of water followed by ethanol. The
washed gold nanoparticles were covered and lowed to dry in air overnight prior to further
use. Isolated particles on mica were analysed by AFM had an average diameter of 4.3 ±
0.8 nm (n=100) and were confirmed using transmission electron microscopy (TEM)
shown below in Figure 2.1.
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For TEM imaging 100 mg mL-1 solution of dodecanthiol gold nanoparticles was
diluted to a final concentration of 2 mg mL-1. The TEM sample was prepared by placing
one drop of the final dispersion on a silica wafer and dried under vacuum. The average
diameter was 4 ,2 nm (Figure 2.1).

Figure 2.1 TEM image of dodecanethiol gold-nanoparticles with average diameters of 4
± 2 nm on 20 nm scale bars.

The gold nanoparticle ink was prepared by dissolving dodecane thio-protected
gold nanoparticles in toluene to a concentration of 100 mg mL-1. The gold nanoparticle
solution was filtered prior to use with a 0.2µm cutoff PTFE filter. 1.5mL of the gold
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nanoparticle ink was injected into a liquid crystal Dimatix printer cartridge immediately
prior to use.
Poly(amic acid) ink was prepared by diluting the 10% (m/m) poly(amic acid)
solution in highly pure N-methyl-2-pyrrolidone (NMP) 1% (m/m). The solution was
gently shaken to mix and the poly(amic acid) was injected into a liquid crystal Dimatix
printer cartridge immediately prior to use.

2.3.4 Array Fabrication
For printing, clean 22 x 28cm polyimide films were placed in the Dimatix printer
and heated to 35oC and secured using the platen vacuum. The gold nanoparticle ink
cartridges were placed in the Dimatix printer and visually checked using the high-speed
drop watcher camera to ensure consistent ink droplet formation. The printer was aligned
with the substrate. The pattern file was set to allow for printing multiple arrays in a single
printing, with varying spacing between arrays. The gold nanoparticle ink was then printed
onto the polyimide film. Following deposition of the gold nanoparticle ink onto the
Kapton substrate, the arrays were heated to 200oC for 3 min or until the films lightened
slightly in color. The films were then briefly rinsed with water and returned to the printer
for application of poly(amic acid) ink. The poly(amic acid) ink was placed in the printer
and the arrays were aligned using the fiducial camera. Five layers of poly(amic acid) ink
were printed over the array leads, leaving the working gold nanoparticle electrodes and
electrical contacts uncovered. Following application of the poly(amic acid) solution to
provide an insulating layer of polyimide on the leads. Surface area and reproducibility of
the electrochemical arrays were estimated by cyclic voltammetry (CV) for a solution of
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4mM potassium ferrocyanide in 100 mM KCl. Scan rates were varied from 100 to 10 mV
s-1 (Figure 2.9).

2.4 Results
Ink made from dodecane thiol-protected gold nanoparticles (AuNPs) dissolved in
toluene was adjusted in concentration to allow reproducible formation of conductive lines
in a single printing to avoid clogging of the inkjets. AuNPs at 100 mg mL-1 in toluene
produced stable inks that could print using the Dimatix printer for twenty- four hours
without clogging the inkjets. However, storage of the ink within the cartridge over a
period of a week was problematic due to slow evaporation of toluene and aggregation of
the AuNPs.
1% polyamic acid by weight in N-methyl-2-pyrrolidone (NMP) having a
kinematic viscosity of 4.28 ± 0.03 cP as measured by a capillary viscometer allowed for
easy inkjet printing of an insulating film. The poly (amic acid) solution printed well
using the custom waveform and printed continuously for 24 h without clogging.
Furthermore, the poly (amic acid) cartridges were stable for a week when stored in a
closed container and printed well following one week of storage.
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Figure 2.2 Jetting and Non-jetting waveforms used for printing both AuNP and poly
(amic acid) inks (shown at 15 V). The two waveforms were consecutively applied based
on the pattern to be printed. The non-jetting waveform helps to prevent bubbles forming
in the jets while the jetting waveform applies a single drop of ink.

An optimized waveform for inkjet printing was employed, that consists of three
steps; first, an increasing voltage period to fill the ink into the liquid crystal printer
cartridges, second, a declining voltage period to dispense the fluid, and finally a segment
that recovers its original shape without drawing air that could form bubbles shown above
in Figure 2.2. This cycle helps to ensure that the cartridge is dispensing perfectly formed
drops. The custom waveform maximum voltage for both non-jetting and jetting was
adjusted prior too printing the patterns. Adjustments to the voltage settings were made by
observing individual drops from the built in drop watch camera within the Dimatix
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printer. All inks were printed reproducibly using this waveform with voltages applied in
the 15-25 V range for jetting and 3-5 V for non-jetting waveform.

Scheme 2.1 Fabrication of AuNP arrays: (A) inkjet printing of the AuNP ink onto the
substrate (Kapton); (B) inkjet printing of the poly (amic acid) to insulate the electrode
leads; (C) the AuNP pattern (gold) overlaid with the poly (amic acid) printed pattern
(orange).

Using the custom waveform, the gold nanoparticle ink was printed in an eight
electrode array pattern (Scheme 2.1). The spacing between drops was set at 15 µm
between each pixel, this spacing provides overlap as each drop spreads with an
approximate 40µm diameter. The pattern was set to print a square working electrode of
dimensions 465 x 465 µm. For each eight- electrode array, approximately 600 mg of gold
was printed. When printed, the gold nanoparticle ink spread as expected, with the effect
being most noticeable on the bottom of the electrode, which was the last portion of the
array to be printed (Figure 2.3).
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A

B

Figure 2.3 Photographs of the array: (A) printed AuNP array with the protective
polyimide insulating film; (B) picture taken using the Dimatix printer’s fiducial camera
showing a typical single AuNP working electrode.

After spreading, the two-dimensional surface area of the arrays resulted in a
geometric area of 0.299 ,0.015 mm2. Following gold nanoparticle printing, the arrays
were sintered for ~ 3 min at 200oC. The arrays slightly lightened in color marking the
loss of the dodecane thiol layer and formation of percolation paths through the gold
nanoparticle network.16 After heating, the dry resistance of gold arrays from contact to
working electrode was 20-25 ohms. Energy- Dispersive X-Ray spectroscopy confirmed
the loss of the dodecanethiol layer. The elemental scan before sintering is shown below in
Figure 2.4 with percentage of sulfur at 3.3%. The elemental scan after is shown in Figure
2.5 with a percentage of sulfur at 1.4% indicating a loss of ~43% once arrays are baked.
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Figure 2.4 EDX pre-sintering elemental scan of the gold arrays.
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Figure 2.5 EDX post-sintering elemental scan of the gold arrays.

Field Emission Scanning Electron Microscopy, FESEM confirmed formation of
percolated paths due to the loss of dodecanethiol layer. Scanning Electron Micrographs
were taken on a Zeiss DSM 982 Gemini FE-SEM with a Schottky Emitter at an
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accelerating voltage range from 2 to 4KV and a beam current of about 1mA. Printed
dodecanethiol AuNPs before sintering is shown in Figure 2.6A indicating large gaps
between the inkjet-printed scans that when heat treated at 200oC for 15mins were
removed dure to loss of the dodecanethiol groups forming the percolated paths as the Au
cores coalesced as shown in Figure 6B and at the same magnification as Figure 2.6A. It
seems as though there are cracks in Figure 6B but on further magnification we can see
that they are just differences in the thickness of layers of the sintered gold Figure 2.6C.
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A

B

C
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Figure 2.6 FESEM micrograph of an electrode on an array before sintering (A) and after
(B) indicating that the Au cores coalesced, then a larger magnification (C) after sintering
to demonstrate that it’s not cracking but different thickness of films.

Poly (amic acid) ink was printed over the sintered gold nanoparticle arrays to
insulate the leads. Poly (amic acid), when heated for 30 mins at 200oC, dehydrates to
form polyimide (Scheme 2), which adheres very strongly to the Kapton polyimide
substrate.17 Imidization of the poly (amic acid) essentially seals the old leads between the
polyimide substrate and the newly formed polyimide coating. Due to the low
concentration of poly (amic acid) in the poly (amic acid) ink, a total of five layers of ink
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were required in the pattern shown in Scheme 2.1. Aligning the gold nanoparticle arrays
for the application of the poly (amic acid) ink was difficult due to its low visibility. A test
pattern consisting of several lines was printed to provide visualization and allow
adjustment of the printing origin. Once aligned five layers of the poly (amic acid) ink
were printed to ensure that the narrow leads were completely insulated. The imidiation
process then formed a protective, insulating polyimide layer over the leads.
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Scheme 2.2 Poly(amic acid) dehydration to give the corresponding polyimide.

The working electrodes of the gold nanoparticle arrays were clearly rough
surfaces with well-defined borders as seen in Figure 2.2. Tapping-mode AFM Figure 2.7
images revealed a rough surface featuring larger hills and valleys superimposed on a
smaller close packed particle landscape consistent with well defined individual AuNPs in
a sintered network. The mean surface roughness was 21, 5nm for the sintered gold
nanoparticle surface, confirming a rough nanostructured electrode surface suitable for
fabrication of an immunosensor.
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Figure 2.7 Tapping mode AFM of one of eight sintered working electrodes in an inkjetprinted gold nanoparticle array.

One of the major advantages of inkjet-printed arrays is the feasibility of large
scale production using industrial inkjet printers. In this study, multiple arrays were
printed in each printing run. An example is shown below in Figure 2.8 where 56 gold
nanoparticle arrays were produced in a single printing.
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Figure 2.8 Kapton substrate after printing 56 eight-electrode AuNP arrays in a single run
(shown within the Dimatix Materials Printer).

Following cleaning, the eight electrodes were scanned simultaneously by cyclic
voltammetry in 1mM potassium ferricyanide solution and 100mM potassium chloride
Figure 9. The electrode The electrochemical surface area of the arrays was determined,
using the oxidation peak current, the Rangles-Sevick equation and the known diffusion
coefficient of ferrocyanide to be 0.35 ,0.01mm2.18 This area is 116% of the geometric
surface area estimated by analysis of fiducial camera images. The working electrodes
showed good reproducibility in electrochemical surface area with a relative standard
deviation from electrode to electrode of < 3%, which is directly relevant to applications
of the array.
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Figure 2.9 Simultaneous cyclic voltammograms of all eight array electrodes in 1 mM
potassium ferricyanide and 100 mM potassium chloride at a scan rate of 100 mV s-1.

2.5 Discussion
Inkjet-printed electronics hold enormous potential for the fabrication of low cost
sensors and devices. A single array described here cost less than 0.2 cents in materials to
produce. The non-contact fabrication of inkjet-printed arrays allowed for the
simultaneous production of a large number of devices that were highly reproducible,
conductive and easily adapted to fabrication of an immunosensor. This could easily be
scaled up to print arrays in larger numbers at lower cost with and industrial-sized inkjet

!

&&!

printer. This ease of modification of the inkjet pattern is a major advantage of the printing
technique. Patterns can be changed in a matter of minutes for prototype development.
This advantage is clear when inkjet printing is compared to either screen-printing or
chemical vapor deposition. While changes in screen-printed or CVD processes require
the development of a new mask or screen, inkjet printed patterns can be simply modified
using conventional artwork programs.
Thiol-protected AuNPs used in this work allowed development of highly stable
ink formations that could be reproducibly printed on heat and chemically resistant Kapton
plastic and sintered. These sintered gold nanoparticle networks had low resistance across
the film and a nanostructured surface. The use of toluene as the solvent for the gold
nanoparticles required a liquid crystal polymer cartridge but for industrial applications
the inkjet reservoir could no doubt be designed to handle the solvent. Printing the poly
(amic acid) insulating layer provided a well-defined, reproducible surface area with < 3%
variation from electrode to electrode. Following the imidization of the poly(amic acid)
solution the arrays were well protected with a stable and flexible coating.

2.6 Summary
The results above demonstrate an elegant, cheap, and simple technique for
fabricating AuNP arrays by direct ink-jet printing. These printed AuNP arrays are readily
adaptable to immunosensor applications as previously developed.19,20,21,22 We are
currently interfacing these eight-electrode arrays to microfluidic devices to provide better
control over mass transport of mediator and peroxide to the electrode surface to eliminate
current oscillations caused by stirring and improve signal/noise. Because the ink-jetted
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pattern is easily modified, fast prototyping of patterns for use in microfluidic devices can
be achieved.
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Chapter Three
Rapid Microfluidic Immunoassays of Cancer Biomarker
Proteins using Disposable Inkjet-printed Gold Nanoparticle
Arrays
!
3.1 Abstract
Conventional immunoassays often take many hours to complete, but more rapid
methods are needed for point-of-care and surgical applications in cancer diagnostics. This
paper describes a low-cost ink-jet printed sensor chip integrated into a simple
microfluidic immunoarray for low sample volume detection of two cancer biomarker
proteins in 8 min. Magnetic beads of 1 mm diam. re derivatized with ~300,000 enzyme
labels and thousands of antibodies to capture the biomarker proteins from samples offline to provide high sensitivity and ultralow detection limits (DL). For an assay time of
45mins, detection limits for interleukin (IL)-6 and IL-8 were as low 19 fg mL-1. We
decreased assay time by sacrificing high sensitivity, and obtained a clinically relevant DL
of 5 pg mL-1 in 8 min. assays. Accuracy was demonstrated by determining IL-6 and IL-8
in conditioned media from head and neck squamous cell carcinoma (HNSCC) cells and
comparing results to those obtained by standard single-protein ELISA. Results indicate
that this immunoarray and protocol could be employed for rapid detection of a wide
range of proteins.
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3.2 Introduction
Despite recent advances in treatment, cancer remains a leading worldwide cause
of human mortality. Current methods of cancer detection are often based on imaging
technologies, such as magnetic resonance imaging (MRI), positron emission tomography
(PET), and computed tomography (CT), which themselves have improved in
performance using new contrast materials and can distinguish between different
anatomical features.1,2,3,4,5 However, these approaches rely on finding and imaging a
tumor, giving limited information on the onset of cancer or quantification of cancerous
cells.1,2,3,4,5 Other techniques are based on cell morphology and microscopy which
involve invasive biopsies to observe cancer cells in tissue.6,7 These tests are not
individually conclusive as biopsies can miss concentrations of cancer cells, especially at
early stages of the disease.6,7 Alternatively, specific biosensor arrays that rapidly measure
multiple biomarker proteins in serum provide hope for future early cancer detection and
monitoring.8,9,10,11,12,13,14 Such sensitive detection schemes for a selective protein panel
whose members are elevated at the onset of cancer are expected to greatly improve
patient prognoses and treatment outcomes and may even lead to cancer prevention.15
Immunosensor microarrays show great potential in targeting specific biomarkers
especially when integrated with microfluidics.15
Interleukin 6 and 8 (IL-6 and IL-8) were chosen as test biomarkers in this study.
These pro-inflammatory cytokines influence all stages of tumor development including
initiation. Progression, and metastasis.16,17 IL-6 and IL-8 have been used to detect and
monitor head and neck squamous cell carcinoma (HNSCC) commonly referred to as oral
cancer.18,19 HNSCC has high mortality rates due to late diagnosis based on current
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methods, mainly relying on visual identification of cancerous lesions.20,21 Serum levels of
IL-6 in patients with oral cancer are commonly ! 20 pg mL-1, whereas healthy
individuals are below 6 pg mL-1.22 Similarly, IL-8 serum levels in oral cancer patients are
usually abover 20 pg mL-1 with concentrations below 13 pg mL-1 observed in healthy
individuals.23 A biosensor for IL-8 in serum was developed by Munge et. al.24 with a
detection limit of 1 fg mL-1 in ~1 hr assay time.24 However, there is a need to rapidly
measure multiple biomarker proteins in surgical applications to inform decisions such as
defining surgical borders and metastasis and to detect and monitor recurrence.25
Effective point of care (POC) sensors must be inexpensive, rapid, adequately
sensitive, and should require limited technical expertise and minimal sample volume.8,9
A number of methods including fluorescence immunoassays,26 PCR-based bar code
labels,27

radioimmunoassay,28

two-dimensional

(2D)

electrophoresis,29

and

multidimensional liquid chromatography- mass spectrometry30 have been used, but most
are limited for POC protein measurements due to cost, assay time, or technical
complexity. Recent approaches to decrease assay times include an Immuno-pillar chip

31

which gives immunoassay in 4 mins for C-reactive-protein using florescence detection.31
Here, a 3D hydrogel format impeded removal of nonspecifically bound antibodies in
wash steps, the assay yielded relatively high detection limits of 100 pg mL-1 for Creactive-protein and ng mL-1 levels for "-fetoprotein and prostate specific antigen (PSA)
in serum.31,32
We recently fabricated disposable inkjet-printed arrays form 4nm gold
nanoparticles (AuNP) that costs less than $ 0.20/ array in materials.33 Preliminary tests of
these gold arrays without microfluidics achieved a detection limit of 20 pg mL-1 for IL-6.

!

'$!

33

To facilitate rapid, semi-automated measurements of proteins in the present work, these

AuNP arrays were integrated into a simple microfluidic device (Scheme 3.1), and protein
analytes were captured for analysis with magnetic beads (MB) bioconjugated with
hundreds of thousands of enzyme labels and secondary antibodies.15

Scheme 3.1 Schematic representation of the disposable injet-printed array incorporated
into a simple microfludic device.

We have also used sensor arrays made from commercial screen-printed carbon arrays
decorated with 5nm AuNPs in a microfluidic system to achieve 1.25 hr assays with
detection limits of 200 fg mL-1 for IL-6 and PSA in serum.15 We later improved
detection limits to 5-5- fg mL-1 for determining four oral cancer biomarker proteins in
serum simultaneously in 50 min assays by using 400,000 horseradish peroxidase (HRP)
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labels per bead.18 The disadvantage here is that the disposable sensor arrays cost about
$10/each and require manual deposition of AuNPs onto a polyion film on each sensor in
the array. The advantage of the printed AuNP immunoarrays in this paper is that they are
printed directly on thermostable plastic at low cost with automatic production of
hundreds of arrays at a time using an inkjet materials printer.
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Here we describe

integration of this low-cost AuNP immunoarray into a microfluidic device to achieve
clinically relevant DLs of ~5 pg mL-1 for IL-6 and IL-8 in 8mins.

3.3 Experimental
3.3.1 Chemicals and Materials
Kapton FPC film (127 mM thick) was purchased from American Durifilm.
Lyophilized 99% bovine serum albumin (BSA), sterile-filtered bovine calf serum, gold
(III) chloride trihydrate, 1-dodecane thiol, tetrocylammonium bromide, sodium
borohydride, 3-Mercaptopropenoic acid (MPA), N-hydroxysulfoscuccinimide (NHSS),
1-Ethyl-3-[-3-dimethylaminopropyl] carbodimmide hydrochloride (EDC), poly(amic
acid), Tween-20, and Hydroquinone (HQ) were purchased from Sigma-Aldrich.
Hydrogen peroxide (H2O2, 30%) came from Fisher Scientific. The poly(dimethoxy)silane
(PDMS) kit was purchased from Dow Corning. MyOne Tosylactivated beads (1 mm
diameter, Dynabeads) and Streptavidin coupled magnetic beads (1 mm diameter,
Dynabeads) were from Invitrogen. Immunoreagents (monoclonal primary antibodies,
BSA, biotinylated secondary antibodies and biotinylated horseradish peroxidase (HRP))
were dissolved in pH 7.2 phosphate saline (PBS) buffer (5.9 mM Na2HPO4, 3.9 mM
NaH2PO4, 2.7 mM KCl, 120 mM NaCl). 400 mM EDC and 100 mM NHSS were
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dissolved in ultrapure water immediately before use. Monoclonial antihuman Interleukin6 (IL-6) antibody (Ab1) (clone no. 6708), biotinylated antihuman IL-6 antibody (biotinAb2), recombinant human IL-6 (carrier-free), human IL-6 polyclonal (goat IgG)
antibody(Ab2), monoclonal antihuman interleukin-8 (IL-8) antibody(AB1) (clone no.
6217), biotinylated antihuman IL-8 antibody(biotin-Ab2), recombinant human IL-8
(carrier-free) were from R&D Systems, Inc. (Minneapolis, MN, USA).

3.3.2 Instrumentation
All electrochemical measurements were made using a CHI 1040A eight-channel
potentiostat simultaneously for all eight electrodes at room temperature. The CHI 1040A
was connected to the microfluidic array system and was used for amperometric detection.
Single-potential amperometry was performed at optimal conditions for high sensitivity
and low ratio signal/noise, -0.2 V vs. Ag/AgCl (0.14 M NaCl) reference with a solution
flow of 100 µL min-1. The microfluidic system was constructed as previously reported by
Chikkaveeraiah et al.15 It featured a molded, soft PDMS slab with a 1.5 mm wide
rectangular channel that was placed on top of the electrode array. As before, the
microfluidic channel was supported by two hard flat poly(methylmethacrylate) (PMMA)
plates manufactured to fit on either side of the PDMS slab and bolted together (Figure
3.1A). The top PMMA plate contained female ports (4 mm diameter) for screwing in
standard male plastic fittings (1.5 mm, up church) to hold 0.2 mm i.d. PEEK connecting
tubing for an inlet and outlet (Figure 3.1A). The top PMMA also contained two holes 0.6
mm for Ag/AgCl and 0.2 mm diameter for Pt wire electrode. For the microfluidic system,
a Harvard 70-4502 pump 11 elite model syringe pump was used. It was connected to the
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inlet through a Rheodyne model 9725i injector valve with a sample loop of 100 mL
through 0.2 mm i.d. tubing (Figure 3.1B).
A Dimatix Materials Printer (model DMP-2800, FUJIFILM Dimatix, Inc. Santa
Clara, CA) was used for all inkjet printing as described previously by Jensen et al.33

Figure 3.1 (A) The disposable ink-jet printed array incorporated into the microfluidic
device consisting of soft PDMS channel and to PMMA plates, the top containing ports
for both inlet and outlet for fluid to flow threw. The top PMMA also contains both the Pt
counter and Ag/AgCl reference electrodes. (B) The experimental set up for the
microfluidic device containing the 8-electrode potentiostat and computer readout.

3.3.3 Fabrication of gold electrode arrays
Gold arrays were fabricated as described previously by Jensen et al. using a
Dimatrix Inkjet materials printer.33 The gold nanoparticle ink was prepared, using toluene
to a concentration of 100 mg mL-1 and filtered with a 0.2 µm cutoff PTFE filter and
injected into a liquid crystal Dimatix printer cartridge immediately prior to use.
!
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the gold was printed, the arrays were then sintered for 15 mins at 200oC.

33

The arrays

lightened in color indicating loss of the dodecane thiol layer and formation of percolated
paths.34 The poly(amic acid) ink was also prepared, as previously reported, 33 by diluting
the 10% (m/m) poly(amic acid) solution in highly pure N-methyl-2-pyrrolidone (NMP) to
1% (m/m) and assed to a liquid crystal Dimatix printer cartridge immediately prior to use.

3.3.4 Preparation of magnetic Ab2-tosyl or streptavidin magnetic beads (MB)-HRP
conjugates
Ab2-MB-HRP bioconjugates were prepared as previously described using either
tosylactivated or streptavidin-coated magnetic beads (Figure 3.2).17,18 As previously noted,
an Invitrogen Dynal magnet was used to help complete all washing and separation steps
required for conjugation of biomolecules to the magnetic beads. Briefly, either 2 mg of
tosyl-MBs or 0.2 mg of streptavidin-MBs were combined with 3 mg HRP and 0.8 mg
Ab2 or 0.2 mg biotin-HRP and 0.8 mg biotin-Ab2 in a microcentrifuge tube. The total
volumes of the conjugation mixtures were ~580 µL for the tosyl-MBs (the bulk of which
consisted of a mixture of 3 M ammonium phosphate buffer and 0.1 M sodium borate
buffer) and ~200 µL for the streptavidin-MBs (beads were suspended in 0.1% BSA in
phosphate buffer). The resulting mixtures were incubated at 37oC in an Invitrogen
Dynabeads MX mixer for either 24 h (tosyl-MBs) or 25 mins (streptavidin-MBs). This
incubation period facilitated conjugation of HRP and Ab2 molecules to the bead surfaces.
After conjugation, beads were washed with either PBS-T20 (tosyl-MBs) or 0.1% BSA in
phosphate buffer (streptavidin-MBs) to remove excess, unbound HRP and Ab2.
Following washing, tosyl-MBs were suspended in 0.5% BSA in PBS and incubated for
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an additional 18 h to remove any remaining unreacted tosyl moieties. After sufficient
washing in 0.1% BSA in phosphate buffer, Ab2-MBtosyl-HRP and Ab2-MBstreptavidin-HRP
were separately suspended in 0.1% BSA in phosphate buffer at 3.2 mg MBs mL-1 and 1
mg MBs mL-1, respectively, and stored at 4oC until further use. Both MB conjugates were
stable for ~14 days.
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Figure 3.2 (A) The covalent attachment of antibodies to the tosyl functionalized
magnetic particles. The tosyl groups act as good leaving groups for surface amine groups
present on antibodies to attach. (B) The complete conjugation prep for both the
attachment of antibodies as well as HRP enzyme labels using tosyl magnetic particles.
(C) The complete conjugation prep for both the attachment of antibodies as well as HRP
enzyme labes using streptavidin magnetic particles.
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3.3.5 Off-line protein capture with tosyl or streptavidin magnetic beads
Previously reported procedures were followed to capture the antigen of interest
(IL-6 or IL-8) from standard solutions that were prepared using undiluted calf serum. 15,18
Capture of antigen was performed using 60 µL of MBs for Ab2-MBtosyl-HRP or Ab2MBstreptavidin-HRP conjugates, respectively, in a microcentrifuge tube. Ab2-MB-HRP
conjugates were mixed with the antigen sample – and 60 µL of sample for either (for
capture using Ab2-MBtosyl-HRP) or (for capture using Ab2-MBstreptavidin-HRP). PBS
containing 0.1% BSA was added to bring the total volume of the mixture to ~400 mL (for
capture using Ab2-MBtosyl-HRP) or (for capture using Ab2-MBstreptavidin-HRP). The
resulting mixture was then vortexed, placed in a mixer, and incubated at 37oC for 25 mins
(for capture using Ab2-MBtosyl-HRP or Ab2-MBstreptavidin-HRP) for shorter assay times this
step was reduced down to 3mins. After this time, Ab2-MB-HRP conjugates with captured
antigen were washed twice with 0.1% BSA in PBS to remove any excess unbound
antigen. Ab2-MBtosyl-HRP or Ab2-MBstreptavidin-HRP conjugates with captured antigen
were suspended in 0.1% BSA in PBS at concentrations of 1024 µg mL-1 MBtosyl and 125
µg mL-1 MBstreptavidin , respectively, and used immediately in immunoassays.

3.3.6 Fabrication of the Immunosensor
Prior to forming the self-assembled monolayers (SAM) on the surface of the gold
arrays with 3-mercaptopropionic acid (MPA), each of the gold arrays were cleaned in
0.18 M sulfuric acid applying 20 sweep segments between -0.2 V and 1.5 V at 100 mV s1

. Once the gold arrays were cleaned, removing any excess oxide species, the arrays were

rinsed with water, then ethanol, and finally submerged in 4 mM (MPA) in ethanol for 24
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hours. Arrays were then washed with ethanol followed by water and dried with nitrogen
gas.
The end carboxylic acids groups from SAM on the array surface were then
activated by placing 1µL of 400 mM EDC and 100 mM NHSS on each electrode (8
electrodes) of the array. The array was then rinsed with water after 10 mins and primary
antibody (Ab1) was attached by amidization between the activated carboxylic groups of
the SAM and the Ab1 (stock solution of 100 µgmL-1) and left overnight in the fridge at
20oC. The following morning, arrays were washed with PBS T-20 followed by PBS. This
was then preceded by addition of 2% BSA to block nonspecific binding (NSB) on the
surface of each array for 1 hour. Once the blocking step was complete, the arrays were
again washed with PBS T-20 followed by PBS. Arrays were then ready to be placed in
the microfluidic device (Figure 3.1). The Ab2-MB-HRP conjugate with off-line captured
IL-6 or IL-8 were injected into the microfluidic channel at a flow rate of 100 µLmin-1.
When the bioconjugate arrived in the channel, as evident by the red-brown MB color,
flow was stopped and incubated for 15 mins on the sensor surface (for shorter assay times,
this step was reduced to 3 mins). The last step was washing with 0.05%Tween-20 in PBS.
Then detection was completed using 1 mM hydroquinone (HQ) that was passed through
the microfluidic channel at 100 µLmin-1. The amperometric signal was generated at -0.2
V vs Ag/AgCl by injecting the mixture of 100 mM H202 and 1 mM HQ in PBS.

3.3.7 Characterization of Array Surfaces After Modification by AFM
Tapping mode AFM images of the working electrode of the Au-arrays after
cleaning in 0.18 M sulfuric acid revealed a mean surface roughness of 26 ± 2 nm (Figure
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3.3A) which is comparable to that previously reported by Jensen et. al.33 The morphology
of the array after the immobilization of Ab1 had a surface roughness of 13 ± 1 nm (Figure
3.3B). The globular features demonstrate the immobilization of Ab1 on the surface with
nearly full coverage across the electrode surface. After full immunoassay was performed
with the introduction of BSA as well as the bioconjugate (Ab2-MB-HRP), which resulted
in filling the space between the primary antibodies, the surface roughness increased to 32
± 2 nm with much larger globular features (Figure 3.3C). The much larger globular
features further demonstrate the immobilization of the full immunoassay on the surface.

Figure 3.3 High resolution tapping mode AFM images of one of the eight sensor
electrodes of (A) a bare AuNP array after cleaning in 0.18M H2SO4 , (B) AuNP array
with Ab1, and (C) AuNP array + Ab1+ bioconjugate (Ab2-MB-HRP).

3.4 Results and Discussion
3.4.1 Characterization of electrode arrays
Prior to each immunoassay, each of the gold arrays were cleaned in 0.18 M
sulfuric acid, applying 20 sweep segments between 1.5 V and -0.2 V at 100 mVs-1. It
shows similar peaks to those found from bulk gold with formation of gold oxide at +1.2

!

(#!

V and reduction back to bulk gold occurring at 0.9 V shown in Figure 3.4A.35 From these
CVs, the active surface area was calculated following Trasatti et. al.36 to be 0.42 (± 0.02)
mm2 for an individual array with RSD < 5%. This is comparable to the surface area
calculated by Jensen et al of 0.35 ± 0.01 mm2 in ferricyanide solution using the RandlesSevcik equation.33 However, the average surface area calculated over 20 arrays was
found to be 0.46 ± 0.1 mm2, giving an RSD of 22%. Therefore, each amperometric
response was surface area corrected due to higher RSD in array-to-array reproducibility.
To further assess the reproducibility of the array, amperometric signals were measured on
all electrodes in the microfluidic device after injection of 100 mM Fe(CN)6

3-/4-

/ 0.1 M

KCL. All eight electrodes of the array gave similar peak currents (Figure 3.4B), with
average 2.3 (± 0.13) x 10-6 Acm-2 (RSD < 6%) demonstrating the minimum cross-talk
between neighboring electrodes of the array.

Figure 3.4 Array reproducibility: (A) CVs at 100 mV s-1 on 8-electrodes of the printed
gold arrays in 0.18 M H2S04. (B) Amperometric response at 0.1 V vs Ag/AgCl in the
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microfluidic device after injection of 100 mL of 100 mM Fe(CN)6

3-/4-

in 100 mM

potassium chloride at 100 mL min-1.

3.4.2 Immunoassay development
All sensor arrays prior to SAM of MPA were first cleaned by cycling in 0.18 M
sulfuric acid to remove gold oxide from the surface. Immunoassay was then developed by
covalently binding primary antibodies onto the SAM layers on each of the gold sensor
surfaces. Using the off-line capture procedure as reported previously,4,39 a single
concentration of each analyte was used per array.
In order to control non-specific binding of the bioconjugates, 2% BSA was
employed along with washing steps containing 0.05% T-20 and PBS. All assay
parameters, including concentrations and incubation times, were optimized to obtain high
sensitivity and low signal to noise. The analyte proteins were captured off-line by the
heavily labeled antibody–equipped magnetic bead conjugates. Once captured, the
bioconjugates were dispersed and then used to fill the sample loop and finally injected
into the microfluidic chamber. The flow was stopped and 15 mins incubation was
allowed to capture bioparticles by antibodies on the electrode surface. This was then
followed by a wash with 0.05% T-20 in PBS.
Once the surface was washed, a mixture of 1 mM HQ mediator and 0.1 mM
H2O2 was injected into the microfluidic device to generate the amperometric response.
The amperometic response is generated by H2O2 activating HRP to the ferryloxy form,
which is reduced by electron mediator HQ. Control experiments contained the full
immunoassay procedure without antigens (IL-6 and IL-8). The total assay time was 45
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mins, this was obtained by adding all times after antigen (IL-6 or IL-8) was added. This
included the first incubation, in the off-line capture format that was 25 mins, the second
incubation, where the conjugate was incubated on the surface of the array, reduced from
15 mins, along with wash steps and detection that took less than 4mins to perform.
Using the above procedures, peak current densities increased logarithmically from
156 fgmL-1 to 3,750 fg mL-1 with tosyl magnetic beads for IL-6 with a detection limit of
156 fgmL-1, which yields a signal that is three times the average standard deviation above
the signal exhibited by the control. Representative amperometric responses are shown in
Figure 3.5A and corresponding calibration in Figure 3.5B, which confirmed the high
sensitivity that the tosyl-MB conjugates could achieve.

Figure 3.5 (A) Amperometric responses of IL-6 at -0.2 V developed by injecting 1 mM
HQ and 0.1 mM H2O2 after capturing analyte -MBtosyl-Ab2-HRP bioconjugates on the
electrodes in the microfluidic device. (B) Corresponding calibration curve y= 2.79x10-5 +
3.27x 10-5 log(x); R= 0.99.
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The Ab2-MBtosyl-HRP conjugate preparation took approximately 42 hours;
therefore, we decided to try streptavidin-coated magnetic particles with a total conjugate
preparation time of 25 minutes in efforts to reduce conjugate preparation time. However,
with a drastic reduction in preparation time, a decrease in sensitivity was observed in the
calibration plot. The streptavidin magnetic beads (MB streptavidin) containing IL-6, had peak
current densities increasing logarithmically from 39 fgmL-1 to 2500 fgmL-1. The
detection limit determined from three times the average standard deviation above the
control was determined to be 78 fgmL-1. Representative amperometric responses are
shown in Figure 3.6A and corresponding calibration in Figure 3.6C. The slope of the
calibration curve was able to demonstrate the slightly lower sensitivity that was achieved
with the shorter MB streptavidin conjugate preparation.
We also obtained a calibration curve for IL-8 in undiluted serum similar to that of
IL-6 with the MB

streptavidin.

As before, we kept the concentration of primary antibody at

100 µgmL-1 and concentration for secondary antibody at 20 µgmL-1. From these optimum
concentrations of antibodies, a calibration plot was obtained. The peak current densities
increased logarithmically from 19 fgmL-1 to 5000 fgmL-1 with streptavidin magnetic
particles for IL-8 with a detection limit of 19 fgmL-1. Representative amperometric
responses are shown in Figure 3.6B and corresponding calibration in Figure 3.6C. The
slopes of the calibration plots for both IL-6 and IL-8 indicated similar sensitivities for
both biomarkers.
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Figure 3.6 Amperometric responses of IL-6 (A) and IL-8 (B) at -0.2 V developed by
injecting 1 mM HQ and 0.1 mM H2O2 after capturing analyte protein- Ab2-MBstreptavidinHRP conjugates on the electrodes in the microfluidic device. (C) Corresponding
calibration curves for IL-6 (in blue), y= 8.91x10-6 + 3.29x 10-6 log(x); R= 0.96, and for
IL-8 (in black) ,y= 7.84x10-6 + 4.31x 10-6 log(x); R=0.96.
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3.4.3 Reducing Total Assay Time
Current methods of protein detection require long incubations leading to long
assay times. Once we obtained calibration curves for really low concentrations of IL-8
and IL-6, we then wanted to try and reduce the entire assay time to below 10 minutes to
further its ability to be used as a point-of-care sensor.

In our assay procedures, total

assay time was obtained by adding all times after antigen (IL-6 or IL-8) was added.
Again, this included the first incubation, in the off-line capture format that was reduced
from 25 mins to 10 mins, and finally down to 3 mins, the second incubation, where the
conjugate was incubated on the surface of the array, reduced from 15 mins to 5 and
finally to 3, along with wash steps and detection that was reduced and took less than 2
mins to perform. We kept a control, containing 0 pgmL-1 of IL-6 , or IL-8 in serum , and
sample, containing 20 pgmL-1 (IL-6) or 10 pgmL-1 (IL-8) for each of the selected assay
times shown in Figure 3.7A (IL-6), and Figure 3.7B (IL-8). Therefore, the overall assay
time from incubation of sample with Ab2-MB-HRP to measurement including wash steps
was 8 mins. By sacrificing detection limits to lower picogram levels rather than
femtogram levels we are able reduce assay times down to 8 mins.
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Figure 3.7 Optimization of assay time for Interleukin-6 reducing the time down to 45, 20,
and 8 mins for (A) IL-6 and (B) IL-8.

To fully demonstrate the assay could be completed in 8 mins, we obtained
calibration curves for both IL-6 and IL-8, keeping the concentration of both primary and
secondary antibodies the same. From the calibration plot of both IL-6, and IL-8 we
observed a detection limits of 5 pgmL-1 which remains in the clinical range for both IL-8
and IL-6.8,9 The peak current densities increased linearly from 5 pgmL-1 to 200 pgmL-1
for both cancer biomarkers. Representative amperometric responses for both IL-6 and
IL-8 at 8 min assay times are shown in Figure 3.8A (IL-6) and Figure 3.8B (IL-8), along
with corresponding calibration curves (Figure 3.8C). Calibration curves shown in Figure
3.7C confirm that high sensitivity can be achieved in spite of the short assay times.
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Figure 3.8 Amperometric responses of IL-6 (A) and IL-8 (B) at -0.2 V developed by
injecting 1 mM HQ and 0.1 mM H2O2 after capturing analyte protein Ab2-MBstreptavidinHRP conjugates on the electrodes in the microfluidic device. (C) Corresponding
calibration curves for IL-6 (in blue), y= 3.49x10-6 + 2.18x 10-6 log(x); R= 0.96, and for
IL-8 (in black) ,y= 0.74 x10-6 + 1.96x 10-6 log(x); R=0.95.
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3.4.4 Assay Validation with Conditioned Media from Oral Cancer Cells
The electrochemical immunosensor was further validated by assaying oral cancer
cell lines. We used secreted levels of human IL-6 and IL-8 in conditioned media from
cell cultures to verify accuracy, due to ELISA requiring considerable human serum for
replicate single protein assays.

Excellent correlations were obtained between the

immunoarray and ELISA results (Figure 3.9A, for IL-6 and Figure 3.9B for IL-8). All of
the representative HNSCC cell lines used (HN12, HN13, and Cal 27) secreted large
amounts (~1000 pgmL-1) of the biomarkers when compared to non-cancer counterparts
(HaCaT) cells.

Figure 3.9 Comparison of immunoarray results with standard ELISA for conditioned
media for cells (HaCaT, HN12, HN13, and Cal 27) for both IL-6 (A) and IL-8 (B).
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Total assay time remained at 8 min when detecting the oral cancer cell lines. Linear
correlation plots for the immunoarray versus ELISA gave slopes close to 1.0 and
intercepts within standard deviation of zero, confirming correlation (Figure 3.10).

Figure 3.10 Correlation plots of immunoarray results with standard ELISA for
conditioned media for cells (HaCaT, HN12, HN13, and Cal 27) for both IL-6 (A), and
IL-8 (B).

3.5 Summary
Results described above demonstrate successful integration of a disposable,
inkjet-printed AuNP immunoarray into a simple microfluidic device for multiple protein
deteminations. Protocols involving off-line capture of proteins on heavily labeled
magnetic beads for singal amplification can be optimized for either ultrasenstitive
detection or rapid clinical assays in 5µL of serum. The AuNP immunoarray offers many
promising features for rapid point-of-care applications, including, low cost, high

!

)#!

sensitivity, and multiplexing, but the current approach still requires moderate technical
expertise. Operational features involving off-line capture, washing and reagent addition
need to be simplified further, and we are currently addressing these issues in our
laboratory.
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Chapter Four
Ultrasensitive Microfluidic Array for Serum ProInflammatory Cytokines and C-Reactive Protein to Assess
Oral Mucositis Risk in Cancer Patients
!
!
!
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Oral mucositis is an inflammatory lesion of oral mucosa caused by high dose
chemo- and/or radiation therapy. These oral lesions adversely impact clinical
management of cancer patients, and can result in hospitalization, infection, and delay of
therapy. There is need for novel technology to aid in predicting severity of oral mucositis
and implementing personalized therapies. We describe here a semi-automated, modular
microfluidic immunoarray optimized for ultrasensitive detection of pro-inflammatory
cytokines involved in pathobiology of oral mucositis. These biomarkers include tumor
necrosis factor (TNF-!), interleukin-6 (IL-6), interleukin-1! (IL-1!), and C-reactive
protein (CRP). Using a modular microfluidic array device, protein analytes were captured
from serum in a capture chamber by 1 µm magnetic beads coated with antibodies and
enzyme labels. These beads are transported downstream to a detection chamber
containing an 8-sensor array coated with glutathione-gold nanoparticles (GSH-AuNP)
and a second set of antibodies to capture the beads with analyte proteins. Ultralow
detection limits of 10-40 fg mL-1 in 5 µL serum were achieved for simultaneous detection
of the four proteins in 30 min, for mass detection limit of 2.5-10 zeptomoles, or as few as
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1500 molecules. Accuracy and diagnostic utility of the arrays was demonstrated by
correlation of levels of the four biomarker proteins in serum from head and neck cancer
patients with results from standard ELISA. This approach may lead to rapid, low-cost
estimates of projected risk for severity of oral mucositis in cancer patients to enable
improved therapeutic management. This general method can be adapted to other protein
panels.

4.2 Introduction
High-dose chemotherapy or radiation utilized for treatment of cancer generates a
complex inflammatory response in mucosal tissue called mucositis. The pathobiology is
characterized by initial up-regulation of reactive oxygen species that can damage adjacent
cells as well as cause activation of cell signaling pathways that escalate the mucosal
injury.1,2 At the clinical level, oral mucositis is a frequent and debilitating complication of
cancer therapies.1,2,3,4 This painful inflammation and ulceration of the oral mucosa can
adversely affect patient’s quality of life, threatens the efficacy of anticancer therapy, and
increases healthcare costs.1,2,3,4,5
Given the clinical and health economic importance of mucositis, there has been an
increasing trajectory of basic and clinical research directed to this cancer treatment
toxicity over the past 15 years. This progress has led to the contemporary pathobiologic
model that includes activation of transcription factor nuclear factor-"B (NF-"B) as a
consequence of chemotherapy and radiotherapy that may contribute to the development
of mucositis.1,2,3,4,5,6,7 Among the many genes up-regulated by activation of NF-"B are
those responsible for production of pro-inflammatory cytokines tumor necrosis factor #
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(TNF-#), interleukin-6 (IL-6) and interleukin-1! (IL-1$).

1,2,3,4,5,6,7

Increased levels of

these cytokines in tissues and peripheral blood coincide with non-hematological toxicity
caused by radiation and chemotherapy and lead to tissue injury and cell apoptosis.2,5,6
Measurements of NF-"B, TNF-#, IL-6 and IL-1$ in the sera of rat models showed that
concentrations

of

these

proteins

increase

following

the

administration

of

chemotherapeutic agents.3 In most cases, these elevations in serum concentrations
occurred subsequent to histological changes associated with alimentary tract mucositis.
Experimental models show that drug-induced inhibition of the production of proinflammatory cytokines TNF-#, IL-6 and IL-1$ lessens the severity and frequency of
mucositis.1,2,5 High levels of C-reactive protein (CRP), another acute-phase protein overexpressed in response to inflammation, have also been detected in sera of patients with
radiation-induced mucositis.8,9
Protein biomarkers in patient samples can be measured with enzyme-linked
immunosorbent assays (ELISAs) or newer bead-based assays10,11,12 with detection limits
in the 1-10 pg mL-1 range. These technologies are limited for clinical and point-of-care
use by cost, time and sample consumption.13 Faster, low-cost, more sensitive,
multiplexed methods are needed for measuring protein biomarkers to provide timely
patient diagnostics.10,13,14,15 For oral mucositis, such multiplexed biomarker measurement
strategies could in the future enhance prediction of severity and frequency of mucositis
based on personalized biomarker profiles at early stages of cancer treatment.
We recently developed a prototype microfluidic electrochemical immunoarray
that is 10-100 times more sensitive and faster than traditional ELISA and bead-based
assays using off-line capture of protein analytes.16,17,18,19,20 Assay protocols employ
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magnetic beads decorated with massive numbers of enzyme labels and antibodies to
efficiently isolate target proteins from serum and greatly enhance sensitivity. Massively
labeled magnetic beads, a modular microfluidic platform, and nanostructured sensor
enable rapid, ultrasensitive, simultaneous detection of biomarker proteins in smallvolume serum samples (~5 µL).16,17,18,19,20 The off-line capture strategy was effectively
used to measure IL-6 and prostate specific antigen (PSA) in serum samples from prostate
cancer patients16 and IL-6, IL-8, vascular endothelial growth factor (VEGF) and VEGF-C
in sera of oral cancer patients.17
In the present paper, we adapt the analyte capture strategy to detect the panel of
biomarkers associated with oral mucositis in serum samples using a semi-automated online capture format. This novel approach adds a protein capture chamber upstream of the
8-sensor detection chamber.21 The modular microfluidic device first delivers the sample
to this capture chamber, where enzyme-labeled magnetic beads equipped with antibodies
capture each target protein. Then, the beads are washed under magnetic control and
delivered to a nanostructured 8-sensor array decorated with a second set of antibodies
that recognize and sort the magnetic bead-bound target proteins. After washing, the
biomarker proteins are measured simultaneously by activation of enzyme labels and
electrochemical detection. We report here the first true multiplexed application of this
technology to simultaneous ultrasensitive detection of 4 proteins.
Target proteins TNF-!, IL-6, IL-1! and CRP were selected for their reported links
to oral mucositis.1,22 These pro-inflammatory cytokines play essential roles in the
regulation of immune response to malignances.23,24 Previous reports demonstrated
markedly elevated serum levels of each of these proteins in patients with head and neck
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(H&N) cancer compared to healthy controls.24 Herein, we demonstrate that the four
proteins can be measured accurately, quickly, and with high sensitivity using the novel
on-line capture microfluidic immunoarray. Ultralow detection limits of 10-40 fg mL-1
were achieved for multiplex detection of the 4 oral mucositis biomarkers in 5 µL serum
(2.5-10 zeptomoles). Accuracy was verified by agreement of ELISA values with
microfluidic immunoassay results for spiked and unspiked serum samples from head and
neck cancer patients undergoing radiation therapy.

4.3 Experimental
4.3.1 Antibodies and Proteins
Tumor Necrosis Factor (TNF-!) Duoset (catalog # DY210), Human C-Reactive
Protein (CRP) Duoset (catalog # DY1707), and Interleukin-1! (IL-1!) Duoset (catalog #
DY201) were from R&D systems, Inc. Human Interleukin-6 (IL-6) standard ELISA kit
(catalog # 900-K16) was from PeproTech. Lyophilized 99% bovine serum albumin
(BSA) and calf serum were from Sigma-Aldrich.

4.3.2 Chemicals
Screen-printed carbon arrays with 8 sensors (700 µm dia.) were from Kanichi
Research, Ltd. !-Glutathione reduced (GSH, 99%), gold (III) chloride trihydrate
(HAuCl4!3H2O, 99.9%), sodium borohydride (99%), poly(diallyldimethylammonium
chloride) (PDDA, MW 100,000-200,000, 20%), 1-(3-(Dimethylamino)propyl)-3ethylcarbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide (NHSS), Tween-20,
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hydroquinone (HQ, ! 99%), lyophilized 99% bovine serum albumin (BSA), and calf
serum were from Sigma-Aldrich. Hydrogen peroxide (H2O2, 30%) was from Fisher. The
polydimethylsiloxane (PDMS) kit was from Dow Corning. Buffer pH 7.4 phosphate
saline (PBS) was 0.01 M in phosphate, 0.14 M NaCl, 2.7 mM KCl. Streptavidin-coated
1!m diameter magnetic beads (SA-MP) were from Life Technologies. All solutions were
prepared with water purified by a Hydro water purification system to 18 M!•cm.

4.3.3 Human Serum Samples
Human serum samples were collected from patients undergoing high-dose
radiation therapy for H&N cancer at the Neag Comprehensive Cancer Center, University
of Connecticut Health Center (UCHC). The study protocol was IRB approved and
written Informed Consent of participants was obtained prior to sample collection. All
samples were stored at or below -80oC until use. Serum samples were assayed directly
and in selected cases spiked with biomarker proteins for validation tests.

4.3.4 Instrumentation
Amperometric measurements were made with a CHI 1040A eight-channel
potentiostat at room temperature at conditions optimized for high sensitivity and low S/N,
i. e. current was measured at all 8 sensors simultaneously with sensor electrodes held at 0.2 V vs. Ag/AgCl reference at solution flow rate 100 !L min-1.
The online microfluidic device features a syringe pump (Harvard, no. 704504),
injector valve (Rhedodyne, 9725i), capture chamber containing a tiny magnetic stir bar, a
switching valve to change the direction of fluid flow, and a detection chamber that
!
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housed sensors, reference and counter electrodes (Figure 4.1).21 The capture chamber
features

a

layer

of

molded,

flexible

PDMS,

contained

between

two

poly(methylmethacrylate) (PMMA) plates to form an oval cylindrical channel 1.5 mm
wide and 100 ± 2 µL in volume that houses a tiny magnetic stir bar. The top PMMA plate
featured two female ports (4 mm diameter) for screwing in standard male plastic fittings
(1.5 mm i.d., Upchurch) to hold 0.2 mm i.d. PEEK connecting tubing for an inlet and
outlet. The detection chamber (Figure 1B) features a layer of molded, flexible PDMS
sandwiched between two PMMA plates to form a rectangular channel 1.5 mm wide and
2.8 cm long and 63 ± 2 µL in volume. The top PMMA plate again features the two female
ports (4 mm diameter) and in addition is equipped with holes for Ag/AgCl reference
electrode (0.6 mm dia.) and Pt counter electrode (0.2 mm dia.). The syringe pump was
connected to two switch valves through a sample injector using 0.2 mm i.d. tubing. The
two valves are used to either direct flow to waste or to the detection chamber.
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Figure 4.1 Illustrated representations of the (A) on-line capture setup featuring syringe
pump, a manual injector, sample loop, capture chamber on-top a magnetic stirrer,
switching valves, detection chamber, 8-channel potentiostat and computer read-out; (B)
the detection chamber that is used to house the 8-electrode array and both the Pt counter
and Ag/AgCl reference electrodes.

4.3.5 Array Fabrication
The carbon electrode arrays were coated with sequential layers of the polycation
PDDA and 5 nm GSH-AuNPs using a layer-by-layer electrostatic adsorption technique as
previously reported.25 The surface carboxyl groups of the GSH-AuNPs were then
activated by EDC and NHSS to attach the primary antibodies (Ab1) to the arrays through
amidization.16,17 The electrode arrays were washed and incubated with 2% BSA in PBS
for 1 hr to block non-specific binding (NSB). For electrochemical measurements, Ab1modified electrode array (Figure 4.2A) was positioned in a detection chamber, which
consisted of a microfluidic channel with reference and counter wire electrodes (Figure
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4.1B). A new AuNP-antibody array was inserted into the detection chamber for each
assay.

Figure 4.2 Immunoassay strategy for detection of the four protein analytes on (A) the
Ab1-modified electrode surface. (B) On-line capture of protein analytes onto the Ab2-MPHRP in the capture chamber to form protein-bead bioconjugates. (C) Amperometric
signal generation by injecting a mixture of 1 mM HQ, electron mediator, and 0.1 mM
H2O2 into the detection chamber.

4.3.6 Preparation of Ab2-magnetic particle-HRP bioconjugates
Both biotinylated secondary antibodies (Ab2) and biotinylated horseradish
peroxidase (HRP) labels were attached to 1%m diameter streptavidin-coated
superparamagnetic beads as previously reported.17 Briefly, 10 µL of magnetic particles
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(10 mg mL-1) were washed three times with 0.1% BSA in PBS pH 7.4 and then
reconstituted with 40 µL of 0.1% BSA in PBS pH 7.4. 40 µL of biotinylated-HRP (2.5
mg mL-1) and 20 µL of the optimal concentration for biotinylated-Ab2 (Figure 3), were
simultaneously added to the magnetic bead particle dispersion. The reaction proceeded at
37oC for 25 mins for the conjugation to occur. Following the conjugation, the beads were
magnetically separated using an Invitrogen DynaMag-spin magnet, and subsequently
washed 3 times with 0.1% BSA in PBS pH 7.4 to remove any non-specifically bound Ab2
and HRP. The conjugate was then reconstituted with 100 %L of 0.1% BSA in PBS and
stored at 4oC. The number of Ab2 per magnetic particle was estimated to be 40,000 (±
5,000) using a bicinchoninic acid assay (BCA) kit.26 In addition the amounts of HRP per
magnetic particle were estimated to be 300,000 (± 27,000) following the 2,2’-Azinobis(3-Ethylbenzthiazoline-6-Sulfonic acid (ABTS) assay.

4.3.7 On-line capture of protein analytes
The microfluidic system was used in concert with Ab2-MP-HRP detection beads
and Ab1-decorated sensor arrays (Figure 4.2). Briefly, 40 %L of Ab2-MP-HRP (1 mg mL1

MPs) was dispersed in 120 %L of 20 mM PBS pH 7.4, loaded into a 100 %L sample

loop and injected at 100 %L min-1 into the capture chamber. Subsequently, biomarker
protein standard (5 %L of protein analyte in 5-fold diluted in calf serum) or patient sample
was loaded into the sample loop and injected into the chamber. For multiplex detection,
a mixture of 20 %L of the Ab2-MP-HRP bioconjugate for each analyte was dispersed in
80 %L of PBS, loaded into the 100 %L sample loop and injected into the reaction chamber,
followed by injection of a mixture of the four analytes diluted in calf serum for standard
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calibrations. Once the capture chamber was filled with sample, flow was stopped for 30
mins to facilitate analyte capture (Figure 4.2B). The protein-Ab2-MP-HRP conjugates
were then washed, dispersed in PBS-Tween-20 and a valve was switched to transport
them into the detection chamber. When protein-Ab2-MP-HRP conjugates filled the
detection chamber, flow was stopped for 15 mins to capture the conjugate beads on the
Ab1 modified sensor surfaces. Buffer flow was then resumed to remove any unbound
conjugate from the microfluidic channel.
The 8 sensors in the array and common Pt counter and Ag/AgCl reference
electrodes were connected to a CHI 1040A multipotentiostat. To generate amperometric
peaks, a mixture of 1 mM hydroquinone (HQ) mediator and 0.1 mM H2O2 was injected
into the microfluidic device through the 100 %L sample loop to activate the HRP labels.
Amperometric signals were measured via the multipotentiostat with the array potential at
-0.2 V vs. Ag/AgCl (0.14 M NaCl).21 HRP on antigen-Ab2-MP-HRP beads is activated
by hydrogen peroxide to give the oxidized ferryloxy form of HRP. The electron mediator
(HQ) then reduces ferryloxy-HRP, regenerating HRP. The signal is developed by the
reduction of oxidized mediator (benzoquinone) at the sensor surface (Figure 4.2C).

4.3.8 Effect of blocking agent
Background signals in our assays result from a combination of direct reduction of
hydrogen peroxide and NSB of the labeled bioconjugate beads on the sensors. The BSA
blocking agent was employed to prevent NSB of macromolecules in the sample that may
interfere with the assay, and binding of labeled-Ab2 on non-antigen sites on the sensor. In
absence of BSA, signals arising from NSB generate large background currents that can
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not be differentiated from those originating from antigen-antibody binding, and are not
proportional to concentration of the antigen (Figure 4.3).

Figure 4.3 The Current response for sensors with/without 2% BSA blocking agent.
4.3.9 Optimization of Secondary Antibody
In order to establish optimal conditions for the immunoassay as well as to
improve both the sensitivity and signal to noise ratio, secondary antibody concentrations
were varied on the magnetic bead conjugates. Optimal secondary antibody concentrations
were obtained using a consistent primary antibody (Ab1) concentration of 100 µg/mL and
employing standard concentrations of 0, 5, 10, and 50 pg mL-1 for IL-6, TNF-", CRP,
and IL-1!. The greatest signal difference between control and sample concentration
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indicated the optimal secondary antibody concentration to be 9 µg mL-1 for IL-6, 20 µg
mL-1 for TNF-", 10 µg mL-1 for CRP, and 10 µg mL-1 for IL-1! (Figure 4.4).

Figure 4.4 Optimization of secondary antibody (Ab2) using a consistent primary antibody
(Ab1) concentration of 100 µg mL-1 and employing standard concentration of 0, 5,10, and
50 pg mL-1 for (A) IL-6, (B) TNF-", (C) CRP, (D) IL-1!. Optimal concentrations were
determined to be 9 µg mL-1 (IL-6), 20 µg mL-1 (TNF-"), 10 µg mL-1 (CRP), and 10 µg
mL-1 (IL-1!).
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4.3.10 Stability of Electrode Arrays modified with capture antibodies
The stability of the capture antibody modified arrays was investigated up to 9
days after modification and found to be stable with minimal change in the response
(Figure 4.5).

Figure 4.5 Stability of the array sensor (n=8 electrodes) modified with capture antibodies.
Signal responses were measured at day 1 and day 9 with very little change.

4.3.11 Specificity of Multiplex Detection
Prior to multiplex detection, the specificity for each of the selected protein
biomarkers was established on a single array for both a control, and sample (Figure 4.4).
The control array featured full immunoassay procedures without protein analytes. The
sample array consisted of a standard mixture of 18 fg mL-1 IL-6, 12 fg mL-1 TNF-", 15 fg
mL-1 CRP, and 22 fg mL-1 IL-1!. Current peaks for control is a combination of residual
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non-specific binding from the bead conjugates (Ab2-MP-HRP) and the direct reduction of
hydrogen peroxide. Figure 4.6 demonstrates selective reproducible peaks with high
signal/ noise ratios.

Figure 4.6 Duplicate responses measured simultaneously for (A) control mixture of 0 fg
mL-1 for IL-6, TNF-", CRP and IL-1!, and (B) standard mixture of 18 fg mL-1 IL-6, 12
fg mL-1 TNF-", 15 fg mL-1 CRP, and 22 fg mL-1 IL-1!, illustrating reproducibility and
selectivity.

4.4 Results
4.4.1 Single Protein Biomarker Detection
Assays were designed to accurately measure normal serum biomarker levels as
well as levels in patients undergoing oral cancer therapy. Reported mean serum levels of
healthy individuals for IL-6, IL-1$, and TNF-# are 10-30 pg mL-1, and 30 µg mL-1 for
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CRP.24 Serum levels before radiation therapy in patients with oral cancer were reported to
increase to 20-190 pg mL-1 for IL-6, IL-1$ and TNF-#, and !30 µg mL-1 for CRP.24
The microfluidic array was first optimized separately for TNF-#, IL-6, IL-1$, and
CRP in 5-fold diluted calf serum, a good surrogate for human serum.27 Optimal surface
concentrations of antibody on each Ab2-MP-HRP conjugate were established prior to
obtaining calibration curves by comparing amperomeic responses between analyte
standards and controls (Figure 4.4). Control experiments featured the full immunoassay
procedure without the protein analyte. Control signals result from a combination of direct
reduction of hydrogen peroxide and NSB of the labeled bioconjugate beads on the
sensors. To minimize NSB, 0.1% BSA was used in the preparation of the magnetic
particle (MP) bioconjugates, while 2% BSA was incubated on sensors for 1 hr prior to
incorporation into the microfluidic device. Further control of NSB was established by
washing with PBS Tween-20 in both capture and detection chamber (See experimental).
Representative amperometric responses for single biomarker protein detection
(Figure 4.7 A,C,E,G) show high sensitivity over at least 3 decades of concentration from
pg mL-1 to the low fg mL-1 range. Amperometric signals were linear with respect to the
log of biomarker concentration from fg mL-1 to low pg mL-1 standards with R2 values of
0.98(

0.02) (Figure 4.7 B,D,F,H). Relative standard deviations (n=8) for single

biomarkers were 8(

3)%. Detection limits measured as three times the standard

deviation above that of the control were 11 fg mL-1 for IL-6, 6 fg mL-1 for TNF-", 11 fg
mL-1 for CRP, and 10 fg mL-1 for IL-1!.
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Figure 4.7 Immunoassay calibration peaks for individual biomarker proteins in 5-fold
diluted calf serum for (A) IL-6, (C) TNF-#, (E) CRP and (G) IL-1$ developed by
injecting a mixture of 1 mM HQ and 0.1 mM H2O2 at -0.2 V vs. Ag/AgCl and the
corresponding calibration plots for (B) IL-6, (D) TNF-#, (F) CRP and (H) IL-$.

4.4.2 Multiplex Detection of IL-6, TNF-!, CRP, and IL-1!.
Based on single protein biomarker detection described above, we progressed to
simultaneous detection of all analyte proteins. Primary antibodies for each protein were
attached to two of the 8-electrodes on the array. HRP-labeled magnetic beads with
antibodies for IL-6, TNF-#, CRP, and IL-1$ were combined, re-dispersed in PBS, and
injected as a mixture into the reaction chamber, followed by injection of a mixture of the
four protein standards. All steps including incubation, washing, transport to detection
chamber and detection were done as described above for single proteins. Binding studies
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related to the four protein analytes showed acceptably low cross-reactivity for all
antibodies (Figure 4.6).
Representative amperometric responses for multiplexed detection (Figure 4.8
A,C,E,G), like those for single protein biomarker detection, demonstrate high sensitivity
in the pg mL-1 to low fg mL-1 range. A linear relationship between amperometric signal
and the log of biomarker concentration was found for fg mL-1 to low pg mL-1 standards
with R2 values of 0.98 ( 0.02) (Figure 4.8 B,D,F,G). Relative standard deviaitons were
6(

3)%. Detection limits were 18 fg mL-1 for IL-6, 10 fg mL-1 for TNF-", 15 fg mL-1

for CRP, and 40 fg mL-1 for IL-1! for multiplex detection. These detection limits were
slightly larger than those found in single protein biomarker detection. However, the
multiplexed detection limits are still 50-100 times lower than those typically obtained
from standard ELISAs.
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Figure 4.8 Amperometric responses for standard protein mixtures in 5-fold diluted calf
serum for (A) IL-6, (C) TNF-#, (E) CRP, and (G) IL-1$, developed by injecting a
mixture of 1 mM HQ and 0.1 mM H2O2 at -0.2 V vs. Ag/AgCl and the corresponding
calibration plots for (B) IL-6, (D) TNF-#, (F) CRP, and (H) IL-$.

4.4.3 Assay validation with Human Serum Samples from H&N Cancer Patients
In order to validate accuracy, we used the microfluidic array to measure the levels
of IL-6, TNF-#, and IL-1$ simultaneously in ten serum samples from head and neck
cancer patients undergoing radiation therapy. For patient samples CRP had to be
measured separately due to its very high concentration in oral cancer patient serum.25 For
CRP, only 8 of the samples were analyzed as two of them had CRP levels well above our
linear range after our standard dilution protocol, and amounts of sample were limited. In
addition, CRP ELISA results were from a single sample run because of limited sample
amounts. Serum samples collected on day 14 of radiation (1, 2, 3), day 35 of radiation (4,
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5, 6, 7) and 21 days post-radiation (8, 9, 10) were used for these accuracy validation
studies (Table 4.1).

Table 4.1 Data on the human serum samples from H&N cancer patients undergoing
radiation treatment. Visit 2 – Day 14 of radiation, Visit 3 – Day 35 of radiation, Visit 4 –
21 days post-radiation (no scales obtained at the visit). Oral Mucositis assessment scores
(OMAS) showing site scoring of ulceration and erythema with maximum score of 5
(severe mucositis). World Health Organization (WHO) oral toxicity scale; 0 (no
mucositis), 1 (erythema of oral mucosa and pain), 2 (Ulceration present, can eat solid
foods), 3 (Ulceration present, diet limited to liquids) and 4 (Ulceration present, no
alimentation possible). Pain scores (0-10 numerical scale); 0 (none) and 10 (most severe).
Pain scores– average and worst pain experienced by the patient since the last visit (one
score for the entire period of 1-5 days between visits).
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Samples (5 %L) were diluted 30-fold in PBS prior to injection into the assay device to
bring concentrations into the linear range of the calibrations. Several patient samples
were spiked with different concentrations of standards to augment accuracy assessment
and analytical recovery of the assay. By spiking the patient samples with 50, 100, 200,
and 500 pg mL-1 of IL-6, TNF-#, and IL-1$ standards, a wider range of concentrations of
the proteins was obtained for more representative correlation plots vs. ELISA. Good
correlation of our results with those obtained from standard single-protein ELISA
measurements are illustrated using bar graphs (Figure 4.9).
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Figure 4.9 Immunoarray and ELISA assay results from serum samples of cancer patient
serum for (A) IL-6, (B) TNF-#, (C) CRP, and (D) IL-1$. S1-S4 corresponds to patient
samples spiked with 50, 100, 200, and 500 pg mL-1 respectively. (*) corresponds to
values below the detection limits of ELISA and (#) corresponds to values above the
dynamic range of the microfluidic immunoarray.

Correlation was also assessed by linear plots of our immunoarray results vs.
single protein ELISAs. Strong correlation between two assays is indicated by slopes
approaching 1.0 and intercepts near 0. For this small sample set (& 10), linear plots
resulted in slopes and R2-values close to 1 and intercepts near 0 for all target proteins
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suggesting relatively good correlation for all the biomarker proteins (Figure 4.10, and
Table 4.2). The correlation plot slope for CRP (0.78) is smaller than that of other proteins.
This may be due to high levels of the protein in the µg mL-1 range requiring 1 millionfold serial dilutions that may generate volumetric errors, in addition to the fact that only
one ELISA assay measurement for CRP was able to be obtained for each sample.
Nevertheless, as with all target proteins, CRP microfluidic immunoassay results gave
self-consistent values for individual samples that were similar to ELISA values for most
of the samples (Figure 4.9).
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Figure 4.10 Linear correlation plots of immunoarray results against those from individual
ELISAs for human serum samples from cancer patients for (A) IL-6, (B) TNF-#, (C)
CRP, and (D) IL-1$. ELISA assays for CRP (C) represent a single trial.
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Table 4.2 Slopes and intercepts of microfluidic immunoassay vs. ELISA correlation plots
for the human serum samples from patients with H&N cancer.

4.5 Discussion
This study demonstrates the ability of the semi-automated microfluidic
immunoassay to rapidly measure four relevant biomarkers for oral mucositis
simultaneously. Massively labeled magnetic beads with 300,000 enzyme labels and
40,000 antibodies were employed to provide very high sensitivity. The presence of large
quantities of antibodies on these beads ensures the capture of antigen proteins at
concentrations much lower than those typically dictated by free antibody dissociation
constants.28,29 Detection limits of 10-40 fg mL-1 for 5 µL of serum (mass detection limits
2.5-10 zeptomoles) were achieved for multiplexed detection of the four proteins reaching
levels far below those that can be achieved by commercial ELISA kits.10,11,13 These
detection limits are also superior to those offered by commercial multiplexed bead-based
methods (Luminex, Roche, Horiba, Mesoscale Discovery, Bio-Rad) which typically
range from 0.5-100 pg mL-1. 10,11,13,30
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Sensitivities of immunoarray assays obtained from the slope of the calibration
curves ranged from 4.18-7.07 !A mL [fg protein]-1 cm-2 for multiplexed detection (Table
3). These sensitivities are comparable to those previously reported in the multiplex
immunoarray detection of IL-6, IL-8, VEGF, and VEGF-C

17

without on-line sample

capture. The microfluidic, on-line capture immunoarray offers an ultrasensitive, rapid,
simple way to simultaneously detect panels of biomarker proteins in serum compared to
commercial multiplexed bead based assays. The total assay time (30 min) and minimal
sample volume requirements (5 µL) are additional factors highlighting the potential
utility of these microfluidic arrays in the clinic.10,31 Although we have optimized the
present assays for ultrasensitive detection, parameters such as number of labels per bead
and incubation time can be tailored for the exact clinical ranges to be measured in serum,
as we have shown on an earlier version of the immunoarray without on-line capture.19
Furthermore, the method is general and can be adapted to other small panels of protein,
and even to protein biomarkers that may be present in much lower levels than in the
samples analyzed here.
The overall accuracy of the assay in complex mixtures was determined by
correlations between immunoarray results with those obtained by standard ELISAs for
human patient serum levels. A clear advantage is the speed, sample size, and multiplicity
of the immunoassays over ELISA, which requires 100 µL serum for each single protein
assay.10 The levels of the four protein biomarkers in the serum samples were comparable
to those previously reported with IL-6, IL-1! and TNF-! in the pg mL-1 range while CRP
was in µg mL-1 range.24 In addition, the levels of the proteins in spiked samples
demonstrate the analytical accuracy of the immunoassay with percentage recovery close
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to 100%. The ability of the arrays to accurately detect individual biomarkers in serum that
contains many hundreds of potentially interfering proteins demonstrates the assay’s
selectivity.
Preliminary correlation analysis of patient sample protein levels assayed in our
work vs. standard metrics of oral mucositis severity suggested a strong correlation with
IL-6, but results are inconclusive due to the limited number of samples. An ongoing
related study by some of us (RVL, LAC, DEP) utilizing a wider range of samples
established tentative correlations with IL-6 and CRP as biomarkers for oral mucositis
(unpublished data).
Future plans include assessing larger cohorts of patient samples at varying stages
of therapy. This approach may ultimately lead to accurate, low-cost, rapid estimates of
projected risk of oral mucositis in cancer patients, enabling improved therapeutic
management. For example, human keratinocyte growth factor-1 (palifermin) is
recommended for the prevention of oral mucositis in patients receiving autologous stem
cell transplants.32 However, this treatment is expensive, requires intravenous infusion,
and is typically not indicated for the patient projected to develop only mild clinical
mucositis. The development of such biomarkers to accurately predict who will develop
severe mucositis can enable such expensive interventions for mucositis to be selectively
used in a cost-effective manner. In turn, this would facilitate optimal delivery of cancer
therapy and improve patient prognosis.
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